

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 10-Q**

---

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the Quarterly Period Ended December 31, 2010

or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**333-147871**

(Commission File Number)

---

**Catalent Pharma Solutions, Inc.**

(exact name of registrant as specified in its charter)

---

**Delaware**

(State or other jurisdiction of incorporation or organization)

**13-3523163**

(I.R.S. Employer Identification No.)

**14 Schoolhouse Road, Somerset, NJ**

(Address of principal executive offices)

**08873**

(Zip code)

**(Registrant's telephone number, including area code) (732) 537-6200**

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

(Note: As a voluntary filer not subject to the filing requirements of Section 13 or 15(d) of the Exchange Act, the registrant has filed all reports pursuant to Section 13 or 15(d) of the Exchange Act during the preceding 12 months as if it were subject to such filing requirements.)

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Non-accelerated filer  (Do not check if a smaller reporting company)

Accelerated filer

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of February 10, 2011, there were 100 shares of the Registrant's common stock, par value \$0.01 per share issued and outstanding.

---

---

CATALENT PHARMA SOLUTIONS, INC.

INDEX TO FORM 10-Q

	<u>Page</u>
Part I. <u>Financial Information</u>	
Item 1. <u>Financial Statements (unaudited)</u>	4
<u>Consolidated Statements of Operations for the Three and Six Months Ended December 31, 2010 and December 31, 2009</u>	4
<u>Consolidated Balance Sheets as of December 31, 2010 and June 30, 2010</u>	5
<u>Consolidated Statement of Changes in Shareholder's Equity as of December 31, 2010</u>	6
<u>Consolidated Statements of Cash Flows for the Six Months Ended December 31, 2010 and December 31, 2009</u>	7
<u>Notes to Unaudited Consolidated Financial Statements</u>	8
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	30
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	42
Item 4. <u>Controls and Procedures</u>	43
Part II. <u>Other Information</u>	43
Item 1. <u>Legal Proceedings</u>	43
Item 1A. <u>Risk Factors</u>	44
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	44
Item 3. <u>Defaults Upon Senior Securities</u>	44
Item 4. <u>[Removed and Reserved]</u>	44
Item 5. <u>Other Information</u>	44
Item 6. <u>Exhibits</u>	45
<u>Signatures</u>	46

## PART I

### Special Note Regarding Forward-Looking Statements

Certain information included in this Quarterly Report on Form 10-Q may be deemed to be “forward-looking statements.” All statements, other than statements of historical facts, included in this Form 10-Q are forward-looking statements. In particular, statements that we make regarding future market trends are forward-looking statements. When used in this document, the words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions are intended to identify forward-looking statements.

These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements are not guarantees of our future performance and are subject to risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements. We disclaim any duty to update any forward-looking statements. Some of the factors that may cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements include, but are not limited to, those described under the section entitled “Risk Factors” in the Catalent Pharma Solution Inc.’s (“Catalent” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2010 and the following:

- our substantial indebtedness;
- our ability to service our outstanding indebtedness and the impact such indebtedness may have on the way we operate our business;
- competition in the industry;
- the continued financial viability and success of our suppliers and customers, including the research and development and other scientific endeavors of our customers;
- product or other liability risks inherent in the design, development, manufacture and marketing of our offerings;
- changes in government regulations or our failure to comply with those regulations or other applicable laws, including environmental, health and safety laws;
- difficulties or delays in providing quality offerings, services and support to our customers, including manufacturing problems and difficulties or delays associated with obtaining requisite regulatory consents or approvals associated with those activities;
- uncertainties relating to general economic, political and regulatory conditions;
- inability to enhance our existing or introduce new technology or service offerings in a timely manner, and technological developments and products offered by our competitors;
- increased costs for the raw materials used by our manufacturing businesses or shortages in these raw materials;
- changes in healthcare reimbursement in the United States or internationally;
- currency risks and other risks associated with international markets;
- tax legislation initiatives or challenges to our tax positions;
- failure to retain or continue to attract senior management or key personnel;
- disruption of, damage to or failure of our information systems;
- acquisition opportunities and our ability to successfully integrate acquired businesses and realize anticipated benefits of such acquisitions;
- the inability to protect our trade secrets and enforce our patent, copyright and trademark rights, and successful challenges to the validity of our patents, copyrights or trademarks and the associated costs;
- certain liabilities in connection with our pension plans;
- the recent financial crisis and current uncertainty in global economic conditions; and
- conflicts of interest with our controlling investors.

We can give no assurances that any of the events anticipated by the forward-looking statements will occur or, if any of them does, what impact they will have on our results of operations and financial condition.

**PART I. FINANCIAL INFORMATION**

**Item 1. FINANCIAL STATEMENTS**

**Catalent Pharma Solutions, Inc. and Subsidiaries**  
**Consolidated Statements of Operations**  
**(in millions)**  
**Unaudited**

	Three Months Ended December 31, 2010	Three Months Ended December 31, 2009	Six Months Ended December 31, 2010	Six Months Ended December 31, 2009
Net revenue	\$ 413.1	\$ 433.5	\$ 815.2	\$ 849.1
Cost of products sold	290.9	315.1	586.0	625.5
Gross margin	122.2	118.4	229.2	223.6
Selling, general and administrative expenses	72.7	76.2	147.5	146.7
Impairment charges and loss/(gain) on sale of assets	(0.5)	0.2	0.1	244.2
Restructuring and other	5.0	4.5	10.6	7.1
Operating income (loss)	45.0	37.5	71.0	(174.4)
Interest expense, net	41.2	44.1	81.8	84.7
Other (income)/expense, net	1.3	(9.5)	13.4	21.1
Earnings/(loss) from continuing operations before income taxes	2.5	2.9	(24.2)	(280.2)
Income tax expense/(benefit)	9.3	18.4	10.7	7.8
Earnings/(loss) from continuing operations	(6.8)	(15.5)	(34.9)	(288.0)
Loss from discontinued operations	—	(5.3)	(0.2)	(6.3)
Net earnings/(loss)	(6.8)	(20.8)	(35.1)	(294.3)
Net earnings/ (loss) attributable to noncontrolling interest	1.4	0.9	0.6	(0.9)
Net earnings/(loss) attributable to Catalent	\$ (8.2)	\$ (21.7)	\$ (35.7)	\$ (293.4)

The accompanying notes are an integral part of these consolidated financial statements.

**Catalent Pharma Solutions, Inc. and Subsidiaries**  
**Consolidated Balance Sheets**  
(in millions, except shares)  
**Unaudited**

	December 31, 2010	June 30, 2010
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 140.7	\$ 164.0
Trade receivables, net	227.4	247.8
Inventories, net	145.1	142.9
Prepaid expenses and other	98.7	94.9
Total current assets	611.9	649.6
Property and equipment, net	755.6	749.6
Other assets:		
Goodwill	876.0	848.9
Other intangibles, net	295.5	299.2
Deferred income taxes	140.8	138.3
Other	41.2	41.8
Total assets	<u>\$ 2,721.0</u>	<u>\$ 2,727.4</u>
<b>LIABILITIES AND SHAREHOLDER'S EQUITY</b>		
Current liabilities:		
Current portion of long-term obligations and other short-term borrowings	\$ 26.4	\$ 30.2
Accounts payable	105.6	127.8
Other accrued liabilities	197.3	224.0
Total current liabilities	329.3	382.0
Long-term obligations, less current portion	2,267.3	2,239.8
Pension liability	104.0	100.6
Deferred income taxes	205.5	198.7
Other liabilities	68.1	69.8
Commitments and contingencies (see Note 13)		
Shareholder's equity:		
Common stock \$0.01 par value; 1,000 shares authorized, 100 shares issued	—	—
Additional paid in capital	1,080.0	1,074.2
Accumulated deficit	(1,323.4)	(1,287.7)
Accumulated other comprehensive loss	(5.7)	(48.5)
Total Catalent shareholder's (deficit)/equity	(249.1)	(262.0)
Noncontrolling interest	(4.1)	(1.5)
Total (deficit)/equity	(253.2)	(263.5)
Total liabilities and equity	<u>\$ 2,721.0</u>	<u>\$ 2,727.4</u>

The accompanying notes are an integral part of these consolidated financial statements

**Catalent Pharma Solutions, Inc. and Subsidiaries**  
**Consolidated Statement of Changes in Shareholder's Equity**  
**(in millions)**  
**Unaudited**

	<u>Common Stock</u>	<u>Additional Paid In Capital</u>	<u>Accumulated Deficit</u>	<u>Accumulated Other Comprehensive Income/(Loss)</u>	<u>Non controlling Interest</u>	<u>Total Equity</u>
Balance at June 30, 2010	\$ —	\$1,074.2	\$ (1,287.7)	\$ (48.5)	\$ (1.5)	\$(263.5)
Equity contributions		3.5				3.5
Comprehensive income (loss):						
Net (loss)/earnings			(35.7)		0.6	
Dividend distribution to noncontrolling interest					(2.6)	
Foreign currency translation adjustments				38.1	(0.6)	
Deferred compensation				0.6		
Change in unrealized gain/(loss) on derivatives				4.1		
Total comprehensive income						4.5
Equity compensation		2.3				2.3
Balance at December 31, 2010	<u>\$ —</u>	<u>\$1,080.0</u>	<u>\$ (1,323.4)</u>	<u>\$ (5.7)</u>	<u>\$ (4.1)</u>	<u>\$(253.2)</u>

The accompanying notes are an integral part of this consolidated financial statement

**Catalent Pharma Solutions, Inc. and Subsidiaries**  
**Consolidated Statements of Cash Flows**  
(in millions)  
Unaudited

	Six Months Ended December 31, 2010	Six Months Ended December 31, 2009
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Net earnings / (loss)	\$ (35.1)	\$ (294.3)
Loss from discontinued operations	(0.2)	(6.3)
Earnings / (loss) from continuing operations	(34.9)	(288.0)
Adjustments to reconcile earnings/(loss) from continued operations to net cash from operations		
Depreciation and amortization	60.1	63.9
Unrealized foreign currency transaction (gains)/ losses, net	8.6	14.7
Amortization of debt financing costs	4.8	4.8
Deferral of interest through utilization of PIK	—	29.0
Asset impairments and (gain)/loss on sale of assets	0.1	244.2
Equity compensation	2.3	0.2
Provision for deferred income taxes	2.3	(6.3)
Provision for bad debts and inventory	5.0	4.8
Change in operating assets and liabilities:		
Decrease/(increase) in trade receivables	29.0	15.0
Decrease/(increase) in inventories	(0.9)	13.1
(Decrease)/increase in accounts payable	(26.7)	(13.0)
Other accrued liabilities and operating items, net	(33.3)	29.9
Net cash provided by/ (used in) operating activities from continuing operations	16.4	112.3
Net cash provided by/ (used in) operating activities from discontinued operations	—	(8.5)
Net cash provided by/ (used in) operating activities	16.4	103.8
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Proceeds from sale of property and equipment	3.6	0.5
Additions to property and equipment	(33.2)	(36.8)
Net cash provided by/ (used in) investing activities from continuing operations	(29.6)	(36.3)
Net cash provided by/ (used in) investing activities from discontinuing operations	—	10.5
Net cash used in investing activities	(29.6)	(25.8)
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Net change in short-term borrowings	(4.8)	(3.6)
Repayments in revolver credit facility	—	(36.0)
Borrowings from revolver credit facility	—	—
Repayments of long-term obligations	(12.6)	(11.7)
Equity contributions	3.5	0.5
Distribution to non controlling interest holder	(2.6)	(1.7)
Net cash (used in)/ provided by financing activities from continuing operations	(16.5)	(52.5)
Net cash (used in)/ provided by from discontinued operations	—	—
Net cash (used in)/ provided by financing activities	(16.5)	(52.5)
Effect of foreign currency	6.4	0.8
<b>NET INCREASE (DECREASE) IN CASH AND EQUIVALENTS</b>	<b>(23.3)</b>	<b>26.3</b>
<b>CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b>	<b>164.0</b>	<b>63.9</b>
<b>CASH AND CASH EQUIVALENTS AT END OF PERIOD</b>	<b>\$ 140.7</b>	<b>\$ 90.2</b>
<b>SUPPLEMENTARY CASH FLOW INFORMATION:</b>		
Interest paid	\$ 79.0	\$ 51.2
Taxes paid	\$ 17.2	\$ 8.6

The accompanying notes are an integral part of these consolidated financial statements

**Catalent Pharma Solutions, Inc. and Subsidiaries**  
**Notes to Unaudited Consolidated Financial Statements**  
**(in millions, except shares)**

**1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

***Business***

Catalent Pharma Solutions, Inc. (“Catalent” or the “Company”) is a direct wholly-owned subsidiary of PTS Intermediate Holdings LLC (“Intermediate Holdings”). Intermediate Holdings is a direct wholly-owned subsidiary of PTS Holdings Corp. (“Parent”) and Parent is 100% owned by Phoenix Charter LLC (“Phoenix”) and certain members of the Company’s senior management. Phoenix is wholly-owned by BHP PTS Holdings L.L.C., an entity controlled by affiliates of The Blackstone Group (“Blackstone”), a global private investment and advisory firm.

***Basis of Presentation***

The accompanying Consolidated Financial Statements are unaudited and should be read in conjunction with the Company’s audited Consolidated Financial Statements and related notes contained in the Company’s Annual Report on Form 10-K as of and for the year ended June 30, 2010. In the opinion of management, all adjustments necessary for a fair presentation have been included. The results reported in these Consolidated Financial Statements should not be taken as indicative of results that may be expected for the entire year. These unaudited consolidated financial statements include the accounts of the Company and all of its subsidiaries. All inter-company transactions have been eliminated.

***Reclassifications***

Certain reclassifications have been made to conform the prior periods consolidated financial statements and notes to the current period presentation including reclassification of the financial results of a site in Schorndorf, Germany from the Packaging Services business unit to the Oral Technologies business unit and certain income tax reclassifications within the guarantor/non guarantor financial statements.

***Use of Estimates***

The preparation of financial statements are in conformity with generally accepted accounting principles (“GAAP”) in the United States which requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts, inventory and long-lived asset valuation, goodwill and other intangible asset impairment, equity-based compensation, income taxes, derivative financial instruments, self insurance accruals, loss contingencies and restructuring charge reserves. Actual amounts may differ from these estimated amounts.

***Revenue Recognition***

In accordance with Accounting Standard Codification (“ASC”) 605 *Revenue Recognition*, the Company recognizes revenue when persuasive evidence of an arrangement exists, product delivery has occurred or the services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Revenue is recognized net of sales returns and allowances. Manufacturing and packaging revenue is recognized either upon shipment or delivery of the product, in accordance with the terms of the contract, which specify when transfer of title occurs. Some of the Company’s manufacturing contracts with its customers have annual minimum purchase requirements. At the end of the contract year, revenue is recognized for the remaining purchase obligation in accordance with the contract terms. Non-product revenue includes service fees, royalty fees, annual exclusivity fees, option fees to extend exclusivity agreements and milestone payments for attaining certain regulatory approvals and is recognized at fair value. Exclusivity payments are paid by customers in return for the Company’s commitment to manufacture certain products for those customers only. The revenue related to these agreements is recognized over the term of the exclusivity agreement or the term of the option agreement unless a particular milestone is designated, in which case revenue is recognized when service obligations or performance have been completed. Arrangements containing multiple revenue generating activities are accounted for in accordance with applicable accounting guidance included within the framework of U.S. GAAP. If the deliverable meets the criteria of a separate unit of accounting, the arrangement revenue is allocated to each element based upon its relative fair value. Generally, in cases where we have multiple contracts with the same customer we treat such contracts as separate arrangements.

***Property and Equipment and Other Definite Lived Intangible Assets***

Property and equipment are stated at cost. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including capital lease assets that are amortized over the shorter of their useful lives or the terms of the respective leases. The Company generally uses the following range of useful lives for its property and equipment categories: buildings and improvements—5 to 50 years; machinery and equipment—3 to 20 years; furniture and fixtures—3 to 10 years. Depreciation

expense was \$45.6 million and \$47.2 million for the six months ended December 31, 2010 and December 31, 2009, respectively. The Company charges repairs and maintenance costs to expense as incurred. The amount of capitalized interest was immaterial for all periods presented.

The Company evaluates the recoverability of its other long-lived assets, including amortizing intangible assets, if circumstances indicate impairment may have occurred pursuant to Codification Standard *ASC 360 Property, Plant and Equipment* (ASC 360). This analysis is performed by comparing the respective carrying values of the assets to the current and expected future cash flows, on an undiscounted basis, to be generated from such assets. If such analysis indicates that the carrying value of these assets is not recoverable, the carrying value of such assets is reduced to fair value through a charge to the Statements of Operations. Fair value is determined based on assumptions the Company believes marketplace participants would utilize and comparable marketplace information in similar arms length transactions. See Note 4 to the unaudited Consolidated Financial Statements for further discussion.

### **Goodwill**

The Company accounts for goodwill and intangible assets with indefinite lives in accordance with Accounting Standard Codification (“ASC”) 350 - *Goodwill – Intangible and Other Assets*, (“ASC 350”). Under ASC 350, goodwill and intangible assets with indefinite lives are no longer amortized, but instead are tested for impairment at least annually. Intangible assets with finite lives, primarily customer relationships and patents and trademarks, continue to be amortized over their useful lives. The Company determines the fair value of its reporting units utilizing estimated future discounted cash flows and incorporates assumptions that it believes marketplace participants would utilize and comparative market information. Goodwill and other indefinite-lived intangible assets are tested for impairment in accordance with ASC 350. The Company’s impairment analysis is based on a discounted cash flow analysis and other valuation methods which incorporate assumptions that it believes marketplace participants would utilize. The discount rate used for impairment testing is based on the risk-free rate plus an adjustment for market and company-specific risk factors. The use of alternative estimates, or adjusting the discount rate used could affect the estimated fair value of the assets and potentially result in more or less impairment. Any identified impairment would result in an adjustment to the Company’s results of operations. See Note 3 to the unaudited Consolidated Financial Statements for further discussion.

### **Recent Financial Accounting Standards**

In April 2010, the FASB issued Accounting Standard Update 2010-17, “*Revenue Recognition – Milestone Method*”, a standard that provides guidance on defining a milestone and determining when it may be appropriate to apply the milestone method of revenue recognition for certain research and development transactions. Under this new standard, a company can recognize as revenue consideration that is contingent upon achievement of a milestone in the period in which it is achieved, if the milestone meets all criteria to be considered substantive. This standard is effective on a prospective basis for periods beginning after July 1, 2010. The adoption of this update did not have a material effect on our consolidated financial statements.

In October 2009, the FASB issued Accounting Standard Update No. 2009-13 “*Multiple Deliverable Revenue Arrangements*”, an amendment to the accounting standards related to the accounting for revenue derived from arrangements with multiple deliverables including how the arrangement consideration is allocated among delivered and undelivered items under the arrangement. Among the amendments, this standard eliminates the use of the residual method for allocating arrangement consideration and requires an entity to allocate the overall consideration to each deliverable based on an estimated selling price of each individual deliverable in the arrangement in the absence of having vendor-specific objective evidence or other third party evidence of fair value of the undelivered items. This standard also provides further guidance on how to determine a separate unit of accounting in a multiple-deliverable revenue arrangement and expands the disclosure requirements about the judgments made in applying the estimated selling price method and how those judgments affect the timing or amount of revenue recognition. We adopted this accounting standard on July 1, 2010 and adoption did not have a material impact on our consolidated financial statements.

## **2. DISCONTINUED OPERATIONS**

The Company completed its sale of the North Raleigh, North Carolina sterile injectables facility on November 13, 2009, to a third party for an amount which approximated fair value. The operating results of this facility are included in the Consolidated Statement of Operations for the three and six months ended December 31, 2009 within discontinued operations.

Summarized Consolidated Statements of Operations data for these discontinued operations are as follows:

(in millions)	Three Months Ended December 31, 2010	Three Months Ended December 31, 2009	Six Months Ended December 31, 2010	Six Months Ended December 31, 2009
Net revenue	\$ —	\$ 1.5	\$ —	\$ 7.1
Loss before income taxes	—	(5.3)	(0.2)	(6.3)
Income tax (benefit)/expense	—	—	—	—
Loss from discontinued operations, net of tax	\$ —	\$ (5.3)	\$ (0.2)	\$ (6.3)

### 3. GOODWILL

The following table summarizes the changes between June 30, 2010 and December 31, 2010 in the carrying amount of goodwill in total and by reporting segment:

(in millions)	Oral Technologies	Sterile Technologies	Packaging Services	Development & Clinical Services	Total
Balance at June 30, 2010	\$ 826.0	\$ —	\$ —	\$ 22.9	\$848.9
Foreign currency translation adjustments	26.2	—	—	0.9	27.1
Balance at December 31, 2010	<u>\$ 852.2</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 23.8</u>	<u>\$876.0</u>

In connection with ASC 350, the Company is required to assess goodwill and other indefinite-lived intangible assets for impairment annually or more frequently if circumstances indicate impairment may have occurred. The Company assesses goodwill for possible impairment by comparing the carrying value of its reporting units to their fair values. The Company determines the fair value of its reporting units utilizing estimated future discounted cash flows and incorporates assumptions that it believes marketplace participants would utilize. The Company uses comparative market information and other factors to corroborate the discounted cash flow results.

During first quarter in fiscal year 2010, the Company concluded that goodwill impairment indicators existed in the Sterile Technologies reporting unit and recorded a non-cash goodwill impairment charge of \$158.3 million. In addition, in connection with the Company's re-organization, certain components were moved out of the Packaging reporting unit and into the Development and Clinical Services unit. This re-organization resulted in allocating a relative fair value of the goodwill associated with the Packaging reporting unit to the new unit and recording a non-cash charge of \$32.4 million.

Impairment charges are recorded within the Consolidated Statements of Operations as Impairment charges and loss/(gain) on sale of assets.

### 4. DEFINITE LIVED LONG-LIVED ASSETS

Other intangible assets with definite lives are being amortized using the straight-line method over periods that range from twelve to twenty years. The details of other intangible assets subject to amortization by class as of December 31, 2010 and June 30, 2010, are as follows:

(in millions)	Weighted Average Life	Gross Intangible	Accumulated Amortization	Net Intangible
December 31, 2010				
Amortized intangibles:				
Core technology	20.0 years	\$ 145.3	\$ (27.6)	\$ 117.7
Customer relationships	12.0 years	51.7	(31.2)	20.5
Product relationships	12.0 years	228.9	(71.6)	157.3
Total amortized intangible assets		<u>\$ 425.9</u>	<u>\$ (130.4)</u>	<u>\$ 295.5</u>

(in millions)	Weighted Average Life	Gross Intangible	Accumulated Amortization	Net Intangible
June 30, 2010				
Amortized intangibles:				
Core technology	20.0 years	\$ 139.0	\$ (22.7)	\$ 116.3
Customer relationships	12.0 years	49.8	(29.7)	20.1
Product relationships	12.0 years	223.4	(60.6)	162.8
Total amortized intangible assets		<u>\$ 412.2</u>	<u>\$ (113.0)</u>	<u>\$ 299.2</u>

Amortization expense for the six months ended December 31, 2010 and 2009 was \$14.5 million and \$16.7 million, respectively.

Amortization expense in future periods is estimated to be:

(in millions)	Remainder fiscal 2011	Fiscal 2012	Fiscal 2013	Fiscal 2014	Fiscal 2015
Amortization expense	\$ 14.5	\$29.1	\$29.1	\$29.1	\$29.1

In conjunction with the goodwill impairment identified in the first quarter of fiscal 2010, the Company completed its review of the impairment of other definite-lived intangible assets under ASC 350 within the Packaging Services segment and Sterile Technologies segment and recorded a non-cash charges to other definite-lived assets impairments of \$9.7 million and \$18.9 million, respectively, on the Consolidated Statement of Operations relating to intangible assets.

During the first quarter of fiscal 2010, the Company also completed the required review of long-lived assets under ASC 360 within the Packaging Services segment to test recoverability and recorded a non-cash charge of approximately \$24.9 million, during the six months ended December 31, 2009.

Impairment charges were recorded within the Consolidated Statements of Operations as Impairment charges and loss/ (gain) on sale of assets.

## 5. DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

### Risk Management Objective of Using Derivatives

The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk primarily by managing the amount, sources and duration of its debt funding and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company's derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company's known or expected cash receipts and its known or expected cash payments principally related to the Company's borrowings.

The Company is exposed to fluctuations in the EUR-USD exchange rate on its investments in foreign operations in Europe. While the Company does not actively hedge against changes in foreign currency, we have mitigated the exposure of our investments in our European operations by denominating a portion of our debt in Euros. At December 31, 2010, the Company had Euro denominated debt outstanding of \$619.0 million that qualifies as a hedge of a net investment in foreign operations. For non-derivatives designated and qualifying as net investment hedges, the effective portion of the translation gains or losses are reported in Accumulated Other Comprehensive Income (Loss) as part of the cumulative translation adjustment. During the six months ended December 31, 2010, the Company recorded \$38.8 million as a loss within cumulative translation adjustment. The net accumulated gain of this net investment as of December 31, 2010 included within Other Comprehensive Income was approximately \$69.9 million. Amounts are reclassified out of Accumulated Other Comprehensive Income into earnings when the hedged net investment is either sold or substantially liquidated.

### Credit Risk Related to Contingent Features

The Company has agreements with each of its derivative counterparties that contain a provision where the Company could be declared in default on its derivative obligations if repayment of the underlying indebtedness is accelerated by the lender due to the Company's default on the indebtedness.

As of December 31, 2010, the terminal value of derivatives in a net liability position, which includes accrued interest but excludes any adjustment for nonperformance risk, related to these agreements was \$52.3 million. The Company has minimum collateral posting thresholds with certain of its derivative counterparties and has posted collateral of \$9.0 million. If the Company had breached any of these provisions at December 31, 2010, it could have been required to settle its obligations under the agreements at their termination value of \$52.3 million.

### Cash Flow Hedges of Interest Rate Risk

The Company's objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. During the first six months of fiscal year 2011, such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt.

The effective portion of changes in the fair value of derivatives designated and that qualify as cash flow hedges for financial reporting purposes is recorded in Accumulated Other Comprehensive Income on the balance sheet and is subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings. The ineffective portion of the change in fair value of the derivatives is recognized directly in earnings.

As of December 31, 2010, the Company had three outstanding interest rate derivatives; two with a combined notional value of \$760 million and one with a notional of €240 million. These instruments are designated for financial accounting purposes as cash flow hedges of interest rate risk. Amounts reported in Accumulated Other Comprehensive Income related to derivatives will be reclassified to interest expense as interest payments are made on the Company's variable-rate debt. As of December 31, 2010, the Company expects to reclassify \$25.0 million from other comprehensive income into interest expense over the next twelve months.

### Non-designated Hedges of Interest Rate Risk

As of December 31, 2010, the Company had a ¥1.75 billion notional value derivative outstanding maturing on May 15, 2013 that was an effective economic hedge but not designated for financial accounting purposes as a hedge instrument. This instrument is not speculative and is used to manage the Company's economic exposure to interest rate movements. Changes in the fair value of derivatives not designated as a hedge for financial accounting purposes are recorded directly into earnings as other expense.

The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the Consolidated Balance Sheet as of December 31, 2010 and June 30, 2010.

(in millions)	Fair Values of Financial Derivative Instruments on the Consolidated Balance Sheets:			
	Liability Derivatives As of December 31, 2010		Liability Derivatives As of June 30, 2010	
	Balance Sheet Location	Fair Value	Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments under ASC 815:				
Interest Rate Swaps	Other accrued liabilities and other liabilities	\$ 50.6	Other accrued liabilities and other liabilities	\$ 54.8
Total derivatives designated as hedging instruments under ASC 815:		\$ 50.6		\$ 54.8
Derivatives not designated as hedging instruments under ASC 815:				
Interest Rate Swaps	Other accrued liabilities and other liabilities	\$ 0.4	Other accrued liabilities and other liabilities	\$ 0.4
Total derivatives not designated as hedging instruments under ASC 815:		\$ 0.4		\$ 0.4

The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the Consolidated Statement of Operations for the three and six months ended December 31, 2010 and December 31, 2009.

(in millions)	Effect of Financial Derivative Instruments on the Consolidated Statement of Operations:							
	Amount of Gain or (Loss) Recognized in AOCI on Derivative (Effective Portion) for the Three and Six Months Ended December 31,		Location of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) for the Three and Six Months Ended December 31,		Location of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion and Amount Excluded from Effectiveness Testing)	Amount of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion and Amount Excluded from Effectiveness Testing) for the Three and Six Months Ended December 31,	
	2010	2009		2010	2009		2010	2009
<b>Derivatives in ASC 815 Hedging Relationships</b>								
<b>Three Months Ended:</b>								
Interest Rate Swaps	\$ 2.0	\$ (2.8)	Interest (expense), net	\$ (6.8)	\$ (5.5)	Other income / (expense), net	\$—	\$(0.1)
<b>Six Months Ended:</b>								
Interest Rate Swaps	\$(9.6)	\$(17.7)	Interest (expense), net	\$(13.7)	\$(10.9)	Other income / (expense), net	\$—	\$(0.5)

Derivatives Not Designated as Hedging Instruments Under ASC 815:	Location of Gain or (Loss) Recognized in Income on Derivative		Amount of Gain or (Loss) Recognized in Income on Derivative for the Three and Six Months Ended December 31,	
	2010	2009	2010	2009
<b>Three Months Ended:</b>				
Interest Rate Swaps			Other income / (expense), net	\$ — \$ 0.1
<b>Six Months Ended:</b>				
Interest Rate Swaps			Other income / (expense), net	\$ — \$ (3.3)

## 6. FAIR VALUE MEASUREMENTS OF FINANCIAL INSTRUMENTS

ASC 820 *Fair Value Measurements and Disclosures* ("ASC 820"), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 defines fair value as the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable:

*Level 1* – Quoted prices in active markets for identical assets or liabilities.

*Level 2* – Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means.

*Level 3* – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and also includes instruments for which the determination of fair value requires significant judgment or estimation.

Fair value under ASC 820 is principally applied to financial assets and liabilities which, for Catalent, include both investments in money market funds and derivative instruments - interest rate swaps. There were no changes from the previously reported classification of financial assets and liabilities. The following table provides a summary of financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2010, aggregated by the level in the fair value hierarchy within which those measurements fall:

(in millions)	Total	Fair Value Measurements using:		
		Level 1	Level 2	Level 3
<b>Liabilities</b>				
Interest rate swaps	\$ 51.0	\$ —	\$ 51.0	\$ —
<b>Liabilities</b>				
Long-term debt and other	\$2,228.8	\$ —	\$ 2,228.8	\$ —

### Cash and Cash Equivalents

The fair value of cash and cash equivalents is estimated on the quoted market price of the investments. The carrying amounts of the Company's cash equivalents approximate their fair value due to the short-term maturity of these instruments.

### Derivative Instruments – Interest Rate Swaps

Currently, the Company uses interest rate swaps to manage interest rate risk on its variable rate long-term debt obligations. The fair value of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash receipts (or payments) and the discounted expected variable cash payments (or receipts). The variable cash payments (or receipts) are based on the expectation of future interest rates (forward curves) and derived from observed market interest rate curves. In addition, to comply with the provision of ASC 820, credit valuation adjustments, which consider the impact of any credit enhancements on the contracts, are incorporated in the fair values to account for potential nonperformance risk. See Footnote 5 - Derivative Instruments and Hedging Activities.

### Long-Term Obligations

The estimated fair value of long-term debt is based on the quoted market prices for the same or similar issues or on the current rates offered for debt of the same remaining maturities and considers collateral, if any.

The carrying amounts and the estimated fair values of financial instruments as of December 31, 2010 and June 30, 2010, are as follows:

(in millions)	December 31, 2010		June 30, 2010	
	Carrying Value	Estimated Fair Value	Carrying Value	Estimated Fair Value
Long-term debt and other	\$2,293.7	\$ 2,228.8	\$2,270.0	\$ 2,070.0
LIBOR interest rate swap	38.1	38.1	39.7	39.7
EURIBOR interest rate swap	12.5	12.5	15.1	15.1
TIBOR interest rate swap	0.4	0.4	0.4	0.4

The estimated fair values are based on quoted market prices for the same or similar instruments and/or the current interest rates offered for debt of the same remaining maturities or estimated discounted cash flows.

## 7. LONG-TERM OBLIGATIONS AND OTHER SHORT-TERM BORROWINGS

Long-term obligations and other short-term borrowings consist of the following at December 31, 2010 and June 30, 2010:

(in millions)	<u>Maturity</u>	<u>December 31, 2010</u>	<u>June 30, 2010</u>
<b>Senior Secured Credit Facilities</b>			
Term loan facility Dollar-denominated	April 2014	\$ 1,022.9	\$1,028.2
Term loan facility Euro-denominated	April 2014	335.9	316.6
9 1/2 % Senior Toggle Notes	April 2015	624.4	624.4
9 3/4 % Senior Subordinated Euro-denominated Notes	April 2017	283.1	265.4
Revolving Credit Agreement, \$350 million facility	April 2013	—	—
Other Obligations		<u>27.4</u>	<u>35.4</u>
Total		2,293.7	2,270.0
Less: current portion and other short-term borrowings		<u>26.4</u>	<u>30.2</u>
Long-term obligations, less current portion short-term borrowings		<u>\$ 2,267.3</u>	<u>\$2,239.8</u>

The Company has the option every six months until April 15, 2011, at its election, to use the payment-in-kind (“PIK”) feature of its \$565 million 9 1/2% /10 1/4 % Senior PIK-Election Notes due 2015 (the “Senior Toggle Notes”) in lieu of making cash interest payments. While the Company had sufficient liquidity to meet its anticipated ongoing needs without use of this PIK feature, the Company elected to do so for the October 15, 2009 and April 15, 2010 interest payment dates as an efficient and cost-effective method to further enhance liquidity in light of the substantial dislocation in the financial markets at that time. During the PIK election period, the Senior Toggle Notes were subject to the PIK interest rate of 10 1/4%. For the interest period ending on October 15, 2010, the Company made such interest payment entirely in cash.

In connection with this election, on April 12, 2010, we delivered notice to The Bank of New York Mellon (formerly known as The Bank of New York), in its capacity as trustee under the indenture for the Company’s outstanding Senior Toggle Notes, that, with respect to the interest due on such notes on the October 15, 2010 interest payment date, the Company would make such interest payment entirely in cash at the cash interest rate of 9.50%. As a result, the entirely cash interest election became the default election and the Company did not elect to change the cash interest election for the final interest election period ending April 15, 2011. Therefore, all remaining interest payments on the Senior Toggle Notes are to be paid entirely in cash in accordance with the terms of the indenture.

## 8. INCOME TAXES

The Company’s provision for income taxes relative to earnings/(loss) from continuing operations before income taxes and noncontrolling interest was a provision of \$10.7 million for the six months ended December 31, 2010, as compared to a provision of \$7.8 million for the six months ended December 31, 2009. Generally, fluctuations in the effective tax rate are primarily due to changes in the U.S. and non-U.S. pretax income resulting from the Company’s business mix and changes in the tax impact of special items and other discrete tax items, which may have unique tax implications depending on the nature of the item. In the normal course of business, we are subject to examination by taxing authorities throughout the world, including such major jurisdictions as the United States, Germany, the United Kingdom and France. With few exceptions, we are no longer subject to non-U.S. income tax examinations for years prior to 2002. Under the terms of the purchase agreement related to the Acquisition, the Company is indemnified by our former parent company for tax liabilities that may arise in the future that relate to tax periods prior to April 10, 2007. The indemnification agreement includes, among other taxes, any and all Federal, state and international income based taxes as well as interest and penalties that may be related thereto. As of December 31, 2010, approximately \$16.8 million of unrecognized tax benefits and related interest is subject to indemnification by our former parent company.

As of December 31, 2010, the Company had a total of \$35.4 million of unrecognized tax benefits. Of this amount, \$18.6 million represents the amount of unrecognized tax benefits, including interest and penalties, which, if recognized, would favorably impact the effective income tax rate. The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense. As of December 31, 2010, the Company had approximately \$8.1 million of accrued interest and penalties related to uncertain tax positions.

## 9. EMPLOYEE RETIREMENT BENEFIT PLANS

Components of the Company's net periodic benefit costs are as follows:

(in millions)	Three Months Ended December 31, 2010	Three Months Ended December 31, 2009	Six Months Ended December 31, 2010	Six Months Ended December 31, 2009
<b>Components of net periodic benefit cost:</b>				
Service cost	\$ 0.7	\$ 0.6	\$ 1.3	\$ 1.2
Interest cost	3.1	3.5	6.2	7.0
Expected return on plan assets	(2.3)	(2.2)	(4.5)	(4.4)
Amortization <sup>(1)</sup>	0.2	0.4	0.4	0.8
Net amount recognized	<u>\$ 1.7</u>	<u>\$ 2.3</u>	<u>\$ 3.4</u>	<u>\$ 4.6</u>

(1) Amount represents the amortization of unrecognized actuarial gains.

## 10. RELATED PARTY TRANSACTIONS

### *Advisor Transaction and Management Fees*

The Company entered into a transaction and advisory fee agreement with Blackstone and certain other Investors in BHP PTS Holdings L.L.C. (the "Investors"), the investment entity controlled by affiliates of Blackstone that was formed in connection with the Investor's investment. The Company pays an annual sponsor advisory fee to Blackstone and the Investors for certain monitoring, advisory and consulting services to the Company. For fiscal 2011 the fee is expected to approximate \$10 million. During the six months ended December 31, 2010, \$5.0 million was expensed and recorded in Selling, General and Administrative expenses in the Consolidated Statement of Operations. The remaining balance is recorded as a pre-paid expense classified within Prepaid and other assets on the consolidated balance sheet.

## 11. COMPREHENSIVE EARNINGS/(LOSS) AND ACCUMULATED OTHER COMPREHENSIVE EARNINGS/(LOSS)

Comprehensive earnings/(loss) for the three and six months ended December 31, 2010 and December 31, 2009 are as follows:

(in millions)	Three Months Ended December 31, 2010	Three Months Ended December 31, 2009	Six Months Ended December 31, 2010	Six Months Ended December 31, 2009
Net loss before allocation to noncontrolling interest	\$ (8.2)	\$ (21.7)	\$ (35.7)	\$ (293.4)
Other comprehensive income/(losses):				
Foreign currency translation adjustments	1.5	1.3	38.1	19.9
Deferred compensation/(benefit)	0.2	(0.2)	0.6	(0.2)
Change in unrealized loss on derivatives	8.9	4.8	4.1	(5.0)
Other Comprehensive income	<u>\$ 10.6</u>	<u>\$ 5.9</u>	<u>\$ 42.8</u>	<u>\$ 14.7</u>
Total comprehensive income/(loss) loss before allocation to noncontrolling interest	2.4	(15.8)	7.1	(278.7)
Comprehensive loss attributable to noncontrolling interest	(1.2)	(0.8)	(2.6)	(2.5)
Comprehensive income/(loss) attributable to Catalent	<u>\$ 1.2</u>	<u>\$ (16.6)</u>	<u>\$ 4.5</u>	<u>\$ (281.2)</u>

At December 31, 2010, accumulated other comprehensive income/(loss) consists of:

(in millions)	Foreign Currency Translation Adjustments	Unrealized Gains/(Losses) on Derivatives	Deferred Compensation	Pension Liability Adjustments	Other Comprehensive Income/(Loss)
Balance at June 30, 2010	\$ 27.9	\$ (49.3)	\$ (0.3)	\$ (26.8)	\$ (48.5)
Activity, net of tax	38.1	4.1	0.6	—	42.8
Balance at December 31, 2010	<u>\$ 66.0</u>	<u>\$ (45.2)</u>	<u>\$ 0.3</u>	<u>\$ (26.8)</u>	<u>\$ (5.7)</u>

## 12. EQUITY BASED COMPENSATION

The following table summarizes the impact of the equity-based compensation expense recorded in the Company's Statement of Operations:

(in millions)	Three Months Ended December 31, 2010	Three Months Ended December 31, 2009	Six Months Ended December 31, 2010	Six Months Ended December 31, 2009
Stock compensation expense in selling, general and administrative	\$ 0.9	\$ 1.3	\$ 2.3	\$ 0.2

The activity of the equity-based compensation program for the six months ended December 31, 2010 is presented below:

	Time Based Awards Number of Shares	Performance Based Awards Number of Shares	Market Based Awards Number of Shares
Balance at June 30, 2010	36,040	11,416	27,408
Granted	1,812	—	—
Exercised	—	—	—
Forfeited	(3,896)	(1,326)	(2,730)
Balance at December 31, 2010	<u>33,956</u>	<u>10,090</u>	<u>24,678</u>

In addition to nonqualified stock options at the six months ended December 31, 2010, the Company had outstanding 3,000 restricted stock units with respect to compensation for a participant to receive shares of common stock equal to the units vested upon settlement.

## 13. COMMITMENTS AND CONTINGENCIES

The Company, along with several pharmaceutical companies, is named as a defendant in one hundred and seventy-five pending civil lawsuits filed by individuals allegedly injured by their use of the prescription acne medication Amnesteem®, a branded generic form of isotretinoin, and in some instances of isotretinoin products made and/or sold by other firms as well. While it is not possible to determine with any degree of certainty the ultimate outcome of these legal proceedings, including making a determination of liability, the Company believes that it has meritorious defenses with respect to the claims asserted against it and intends to vigorously defend its position.

From time to time the Company may be involved in legal proceedings arising in the ordinary course of business, including, without limitation, inquiries and claims concerning environmental contamination as well as litigation and allegations in connection with acquisitions, product liability, manufacturing or packaging defects, and claims for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of which could be significant. The Company intends to vigorously defend ourselves against such other litigation and does not currently believe that the outcome of any such other litigation will have a material adverse effect on the Company's financial statements.

#### 14. SEGMENT INFORMATION

The Company conducts its business within the following operating segments: Softgel Technologies, Modified Release Technologies, Sterile Technologies, Packaging Services and Development & Clinical Services. The Softgel and Modified Release Technology segments are aggregated into one reportable operating segment – Oral Technologies. The Company evaluates the performance of its segments based on segment earnings before noncontrolling interest, other (income) expense, impairments, restructuring costs, interest expense, income tax (benefit)/expense, and depreciation and amortization (“Segment EBITDA”). EBITDA from continuing operations is consolidated earnings from continuing operations before interest expense, income tax (benefit)/expense, depreciation and amortization and is adjusted for the income or loss attributable to non controlling interest. The Company’s presentation of Segment EBITDA and EBITDA from continuing operations may not be comparable to similarly-titled measures used by other companies.

The following tables include net revenue and Segment EBITDA during the three and six months ended December 31, 2010:

(in millions)	Three Months Ended December 31, 2010	Three Months Ended December 31, 2009	Six Months Ended December 31, 2010	Six Months Ended December 31, 2009
<b>Oral Technologies</b>				
Net revenue	\$ 261.5	\$ 262.1	\$ 505.5	\$ 509.2
Segment EBITDA	66.6	62.6	118.8	112.3
<b>Sterile Technologies</b>				
Net revenue	53.7	60.8	107.4	122.2
Segment EBITDA	8.3	8.0	13.5	18.5
<b>Packaging Services</b>				
Net revenue	62.3	77.6	130.6	150.0
Segment EBITDA	0.6	7.2	3.7	10.8
<b>Development and Clinical Services</b>				
Net revenue	42.2	41.9	85.6	82.4
Segment EBITDA	8.7	7.7	17.6	13.5
<b>Inter-segment revenue elimination</b>	(6.6)	(8.9)	(13.9)	(14.7)
<b>Unallocated Costs<sup>(1)</sup></b>	(11.2)	(7.9)	(36.5)	(285.8)
<b>Combined Total</b>				
Net revenue	413.1	433.5	815.2	849.1
EBITDA from continuing operations	\$ 73.0	\$ 77.6	\$ 117.1	\$ (130.7)

- (1) Unallocated costs include special items, equity-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:

(in millions)	Three Months Ended December 31, 2010	Three Months Ended December 31, 2009	Six Months Ended December 31, 2010	Six Months Ended December 31, 2009
Impairment charges and gain/(loss) on sale of assets	\$ 0.5	\$ (0.2)	\$ (0.1)	\$ (244.2)
Equity compensation	(0.9)	(1.3)	(2.3)	(0.2)
Restructuring and other special items	(7.0)	(8.3)	(15.2)	(12.1)
Sponsor advisory fee	(2.5)	(2.5)	(5.0)	(5.0)
Noncontrolling interest	(1.4)	(0.9)	(0.6)	0.9
Other income (expense), net	(1.3)	9.5	(13.4)	(21.1)
Non-allocated corporate costs, net	1.4	(4.2)	0.1	(4.1)
Total unallocated costs	<u>\$ (11.2)</u>	<u>\$ (7.9)</u>	<u>\$ (36.5)</u>	<u>\$ (285.8)</u>

Provided below is a reconciliation of earnings/(loss) from continuing operations to EBITDA from continuing operations:

(in millions)	Three Months Ended December 31, 2010	Three Months Ended December 31, 2009	Six Months Ended December 31, 2010	Six Months Ended December 31, 2009
Earnings/(loss) from continuing operations	\$ (6.8)	\$ (15.5)	\$ (34.9)	\$ (288.0)
Depreciation and amortization	30.7	31.5	60.1	63.9
Interest expense, net	41.2	44.1	81.8	84.7
Income tax benefit/(expense)	9.3	18.4	10.7	7.8
Noncontrolling interest	(1.4)	(0.9)	(0.6)	0.9
EBITDA	<u>\$ 73.0</u>	<u>\$ 77.6</u>	<u>\$ 117.1</u>	<u>\$ (130.7)</u>

The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the Consolidated Financial Statements:

(in millions)	December 31, 2010	June 30, 2010
<b>Assets</b>		
Oral Technologies	\$ 2,388.2	\$2,318.3
Sterile Technologies	232.5	216.2
Packaging Services	190.4	194.0
Development and Clinical Services	329.8	314.0
Corporate and eliminations	(419.9)	(315.1)
Total assets	<u>\$ 2,721.0</u>	<u>\$2,727.4</u>

## 15. SUPPLEMENTAL BALANCE SHEET INFORMATION

Supplementary balance sheet information at December 31, 2010 and June 30, 2010, is detailed in the following tables.

### Inventories

Work-in-process and finished goods inventories include raw materials, labor and overhead. Inventories consisted of the following:

(in millions)	December 31, 2010	June 30, 2010
Raw materials and supplies	\$ 85.1	\$ 82.1
Work-in-process	23.1	27.3
Finished goods	51.4	52.1
Total inventory, gross	159.6	161.5
Inventory reserves	(14.5)	(18.6)
Total inventory, net	<u>\$ 145.1</u>	<u>\$142.9</u>

### Prepaid and other assets

Prepaid and other assets consist of the following:

(in millions)	December 31, 2010	June 30, 2010
Prepaid expenses	\$ 16.7	\$ 19.1
Spare parts supplies	10.7	12.3
Deferred taxes	20.6	17.5
Other current assets	50.7	46.0
Total prepaid and other assets	<u>\$ 98.7</u>	<u>\$ 94.9</u>

### Property and equipment

Property and equipment consists of the following:

(in millions)	December 31, 2010	June 30, 2010
Land, buildings and improvements	\$ 441.1	\$ 407.7
Machinery and equipment	531.5	507.4
Furniture and fixtures	12.3	9.5
Construction in progress	44.3	69.7
Property and equipment, at cost	1,029.2	994.3
Accumulated depreciation	(273.6)	(244.7)
Property and equipment, net	<u>\$ 755.6</u>	<u>\$ 749.6</u>

### Other assets

Other assets consist of the following:

(in millions)	December 31, 2010	June 30, 2010
Deferred long term debt financing costs	\$ 30.2	\$ 34.3
Other	11.0	7.5
Total other assets	<u>\$ 41.2</u>	<u>\$ 41.8</u>

## Other accrued liabilities

Other accrued liabilities consist of the following:

(in millions)	December 31, 2010	June 30, 2010
Accrued employee-related expenses	\$ 59.4	\$ 72.8
Restructuring accrual	13.5	15.6
Deferred income tax	—	0.3
Accrued interest	18.4	17.8
Interest rate swaps	25.0	24.0
Deferred revenue and fees	16.6	19.6
Accrued income tax	21.9	30.1
Other accrued liabilities and expenses	42.5	43.8
Total other accrued liabilities	<u>\$ 197.3</u>	<u>\$224.0</u>

## 16. SUBSEQUENT EVENTS

In the preparation of its consolidated financial statements, the Company completed an evaluation of the impact of any subsequent events and determined there were no subsequent events requiring disclosure in or adjustment to these financial statements.

## 17. GUARANTOR AND NON GUARANTOR FINANCIAL STATEMENTS

All obligations under the senior secured credit agreement, the Senior Toggle Notes and the €225 million 9<sup>3</sup>/<sub>4</sub>% Euro-denominated Senior Subordinated Notes due 2017 (the “Senior Subordinated Notes”) are unconditionally guaranteed by each of the Company’s existing U.S. wholly-owned subsidiaries, other than the Company’s Puerto Rico subsidiaries, subject to certain exceptions.

The following condensed financial information presents the Company’s Consolidating Balance Sheet as of December 31, 2010 and as of June 30, 2010 and the Consolidating Statements of Operations for three and six months ended December 31, 2010 and December 31, 2009 and Cash Flows for the six months ended December 31, 2010 and December 31, 2009 for: (a) Catalent Pharma Solutions, Inc. (“Issuer” and/or “Parent”); (b) the guarantor subsidiaries; (c) the non-guarantor subsidiaries and (d) elimination and adjustment entries necessary to combine the Issuer/Parent with the guarantor and non-guarantor subsidiaries on a consolidated basis, respectively.

Catalent Pharma Solutions, Inc. and Subsidiaries  
Consolidating Statements of Operations  
For the Three Months Ended December 31, 2010  
(In millions)

	<u>Issuer</u>	<u>Guarantor</u>	<u>Non- Guarantor</u>	<u>Eliminations</u>	<u>Consolidated</u>
Net revenue	\$ —	\$ 152.6	\$ 265.1	\$ (4.6)	\$ 413.1
Cost of products sold	—	95.1	200.4	(4.6)	290.9
Gross margin	—	57.5	64.7	—	122.2
Selling, general and administrative expenses	0.9	42.4	29.4	—	72.7
Impairment charges and (gain)/loss on sale of assets	—	(0.3)	(0.2)	—	(0.5)
Restructuring and other	—	3.3	1.7	—	5.0
Operating earnings/(loss)	(0.9)	12.1	33.8	—	45.0
Interest expense, net	40.3	0.8	0.1	—	41.2
Other (income)/expense, net	(33.5)	(45.8)	6.1	74.5	1.3
Earnings/(loss) from continuing operations before income taxes	(7.7)	57.1	27.6	(74.5)	2.5
Income tax (benefit)/expense	0.5	1.9	6.9	—	9.3
Earnings/(loss) from continuing operations	(8.2)	55.2	20.7	(74.5)	(6.8)
Loss from discontinued operations	—	—	—	—	—
Net earnings/(loss)	(8.2)	55.2	20.7	(74.5)	(6.8)
Net earnings/(loss) attributable to noncontrolling interest	—	—	1.4	—	1.4
Net earnings/(loss) attributable to Catalent	<u>\$ (8.2)</u>	<u>\$ 55.2</u>	<u>\$ 19.3</u>	<u>\$ (74.5)</u>	<u>\$ (8.2)</u>

Catalent Pharma Solutions, Inc. and Subsidiaries  
Consolidating Statements of Operations  
For the Six Months Ended December 31, 2010  
(In millions)

	<u>Issuer</u>	<u>Guarantor</u>	<u>Non- Guarantor</u>	<u>Eliminations</u>	<u>Consolidated</u>
Net revenue	\$ —	\$ 295.5	\$ 530.6	\$ (10.9)	\$ 815.2
Cost of products sold	—	193.4	403.5	(10.9)	586.0
Gross margin	—	102.1	127.1	—	229.2
Selling, general and administrative expenses	2.3	86.5	58.7	—	147.5
Impairment charges and (gain)/loss on sale of assets	0.2	(0.1)	—	—	0.1
Restructuring and other	—	6.0	4.6	—	10.6
Operating earnings/(loss)	(2.5)	9.7	63.8	—	71.0
Interest expense, net	80.0	1.6	0.2	—	81.8
Other (income)/expense, net	(47.6)	(58.8)	35.4	84.4	13.4
Earnings/(loss) from continuing operations before income taxes	(34.9)	66.9	28.2	(84.4)	(24.2)
Income tax (benefit)/expense	0.8	3.5	6.4	—	10.7
Earnings/(loss) from continuing operations	(35.7)	63.4	21.8	(84.4)	(34.9)
Loss from discontinued operations	—	—	(0.2)	—	(0.2)
Net earnings/(loss)	(35.7)	63.4	21.6	(84.4)	(35.1)
Net earnings/(loss) attributable to noncontrolling interest	—	—	0.6	—	0.6
Net earnings/(loss) attributable to Catalent	<u>\$(35.7)</u>	<u>\$ 63.4</u>	<u>\$ 21.0</u>	<u>\$ (84.4)</u>	<u>\$ (35.7)</u>

Catalent Pharma Solutions, Inc. and Subsidiaries  
Consolidating Statements of Operations  
For the Three Months Ended December 31, 2009  
(In millions)

	<u>Issuer</u>	<u>Guarantor</u>	<u>Non- Guarantor</u>	<u>Eliminations</u>	<u>Consolidated</u>
Net revenue	\$ —	\$ 160.2	\$ 278.0	\$ (4.7)	\$ 433.5
Cost of products sold	—	105.7	214.1	(4.7)	315.1
Gross margin	—	54.5	63.9	—	118.4
Selling, general and administrative expenses	1.3	45.0	29.9	—	76.2
Impairment charges and (gain)/loss on sale of assets	—	—	0.2	—	0.2
Restructuring and other	—	2.0	2.5	—	4.5
Operating earnings/(loss)	(1.3)	7.5	31.3	—	37.5
Interest expense, net	40.3	—	3.8	—	44.1
Other (income)/expense, net	(20.1)	(42.3)	(42.4)	95.3	(9.5)
Earnings/(loss) from continuing operations before income taxes	(21.5)	49.8	69.9	(95.3)	2.9
Income tax (benefit)/expense	0.2	1.5	16.7	—	18.4
Earnings/(loss) from continuing operations	(21.7)	48.3	53.2	(95.3)	(15.5)
Loss from discontinued operations	—	(5.3)	—	—	(5.3)
Net earnings/(loss)	(21.7)	43.0	53.2	(95.3)	(20.8)
Net earnings/(loss) attributable to noncontrolling interest	—	—	0.9	—	0.9
Net earnings/(loss) attributable to Catalent	<u>\$(21.7)</u>	<u>\$ 43.0</u>	<u>\$ 52.3</u>	<u>\$ (95.3)</u>	<u>\$ (21.7)</u>

Catalent Pharma Solutions, Inc. and Subsidiaries  
Consolidating Statements of Operations  
For the Six Months Ended December 31, 2009  
(In millions)

	<u>Issuer</u>	<u>Guarantor</u>	<u>Non- Guarantor</u>	<u>Eliminations</u>	<u>Consolidated</u>
Net revenue	\$ —	\$ 311.7	\$ 547.3	\$ (9.9)	\$ 849.1
Cost of products sold	—	210.1	425.3	(9.9)	625.5
Gross margin	—	101.6	122.0	—	223.6
Selling, general and administrative expenses	0.2	86.5	60.0	—	146.7
Impairment charges and (gain)/loss on sale of assets	—	205.4	38.8	—	244.2
Restructuring and other	—	3.9	3.2	—	7.1
Operating earnings/(loss)	(0.2)	(194.2)	20.0	—	(174.4)
Interest expense, net	81.7	—	3.0	—	84.7
Other (income)/expense, net	211.0	(51.5)	(7.8)	(130.6)	21.1
Earnings/(loss) from continuing operations before income taxes	(292.9)	(142.7)	24.8	130.6	(280.2)
Income tax (benefit)/expense	0.5	3.7	3.6	—	7.8
Earnings/(loss) from continuing operations	(293.4)	(146.4)	21.2	130.6	(288.0)
Loss from discontinued operations	—	(6.3)	—	—	(6.3)
Net earnings/(loss)	(293.4)	(152.7)	21.2	130.6	(294.3)
Net earnings/(loss) attributable to noncontrolling interest	—	—	(0.9)	—	(0.9)
Net earnings/(loss) attributable to Catalent	<u>\$(293.4)</u>	<u>\$ (152.7)</u>	<u>\$ 22.1</u>	<u>\$ 130.6</u>	<u>\$ (293.4)</u>

Catalent Pharma Solutions, Inc. and Subsidiaries  
Consolidating Balance Sheet  
December 31, 2010  
(In millions)

	Issuer	Guarantor	Non-Guarantor	Eliminations	Consolidated
<b>Assets</b>					
<b>Current Assets</b>					
Cash and equivalents	\$ 1.2	\$ 17.8	\$ 121.7	\$ —	\$ 140.7
Trade receivables, net	—	73.2	154.2	—	227.4
Intercompany receivables	—	318.2	662.6	(980.8)	—
Inventories, net	—	36.3	108.8	—	145.1
Prepaid expenses and other	22.2	25.8	50.7	—	98.7
Total current assets	23.4	471.3	1,098.0	(980.8)	611.9
Property and equipment, net	—	326.5	429.1	—	755.6
Goodwill, net	—	308.1	567.9	—	876.0
Other intangibles, net	—	99.5	196.0	—	295.5
Investment in subsidiaries	2,883.5	—	—	(2,881.9)	1.6
Intercompany long-term receivable	—	—	—	—	—
Deferred income taxes	7.7	98.0	35.1	—	140.8
Other assets	31.7	4.2	5.3	(1.6)	39.6
Total assets	<u>\$ 2,946.3</u>	<u>\$ 1,307.6</u>	<u>\$ 2,331.4</u>	<u>\$ (3,864.3)</u>	<u>\$ 2,721.0</u>
<b>Liabilities and Shareholder's Equity</b>					
<b>Current Liabilities</b>					
Current portion of long-term obligations & other short-term borrowings	\$ 14.1	\$ 2.2	\$ 10.1	\$ —	\$ 26.4
Accounts payable	—	23.6	82.0	—	105.6
Intercompany accounts payable	772.9	—	—	(772.9)	—
Other accrued liabilities	44.9	71.5	80.9	—	197.3
Total current liabilities	831.9	97.3	173.0	(772.9)	329.3
Long-term obligations, less current portion	2,252.3	0.7	14.3	—	2,267.3
Intercompany long-term debt	41.7	61.1	106.0	(208.8)	—
Pension liability	—	20.6	83.4	—	104.0
Deferred income taxes	11.9	125.5	68.1	—	205.5
Other liabilities	25.6	19.3	23.2	—	68.1
<b>Shareholder's Equity:</b>					
Common stock \$0.01 par value; 1,000 shares authorized, 100 shares issued	—	—	—	—	—
Additional paid in capital	1,080.0	—	—	—	1,080.0
Shareholder's equity	—	991.2	1,891.4	(2,882.6)	—
Accumulated deficit	(1,323.4)	—	—	—	(1,323.4)
Accumulated other comprehensive income/(loss)	26.3	(8.1)	(23.9)	—	(5.7)
Total shareholder's equity	(217.1)	983.1	1,867.5	(2,882.6)	(249.1)
Noncontrolling interest	—	—	(4.1)	—	(4.1)
Total equity	(217.1)	983.1	1,863.4	(2,882.6)	(253.2)
Total liabilities and shareholder's equity	<u>\$ 2,946.3</u>	<u>\$ 1,307.6</u>	<u>\$ 2,331.4</u>	<u>\$ (3,864.3)</u>	<u>\$ 2,721.0</u>

Catalent Pharma Solutions, Inc. and Subsidiaries  
Consolidating Balance Sheet  
June 30, 2010  
(In millions)

	Issuer	Guarantor	Non-Guarantor	Eliminations	Consolidated
<b>Assets</b>					
<b>Current Assets</b>					
Cash and equivalents	\$ 17.7	\$ 31.7	\$ 114.6	\$ —	\$ 164.0
Trade receivables, net	—	72.4	175.4	—	247.8
Intercompany receivables	—	247.8	644.1	(891.9)	—
Inventories, net	—	35.0	107.9	—	142.9
Prepaid expenses and other	22.4	25.4	47.1	—	94.9
Assets held for sale	—	—	—	—	—
<b>Total current assets</b>	<b>40.1</b>	<b>412.3</b>	<b>1,089.1</b>	<b>(891.9)</b>	<b>649.6</b>
Property and equipment, net	—	334.8	414.8	—	749.6
Goodwill, net	—	308.0	540.9	—	848.9
Other intangibles, net	—	103.3	195.9	—	299.2
Investment in subsidiaries	2,799.1	—	—	(2,797.4)	1.7
Inter-company loan receivable	—	—	—	—	—
Deferred income taxes	7.7	97.9	32.7	—	138.3
Other assets	36.0	4.2	1.5	(1.6)	40.1
<b>Total assets</b>	<b>\$ 2,882.9</b>	<b>\$1,260.5</b>	<b>\$2,274.9</b>	<b>\$ (3,690.9)</b>	<b>\$ 2,727.4</b>
<b>Liabilities and Shareholder's Equity</b>					
<b>Current Liabilities</b>					
Current portion of long-term obligations & other short-term borrowings	\$ 13.9	\$ 6.2	\$ 10.1	\$ —	\$ 30.2
Accounts payable	—	25.0	102.8	—	127.8
Intercompany accounts payable	682.1	—	—	(682.1)	—
Other accrued liabilities	42.9	87.1	94.0	—	224.0
Liabilities held for sale	—	—	—	—	—
<b>Total current liabilities</b>	<b>738.9</b>	<b>118.3</b>	<b>206.9</b>	<b>(682.1)</b>	<b>382.0</b>
Long-term obligations, less current portion	2,220.8	1.4	17.6	—	2,239.8
Intercompany long-term debt	34.3	58.5	116.9	(209.7)	—
Pension liability	—	20.8	79.8	—	100.6
Deferred income taxes	11.3	122.6	64.8	—	198.7
Other liabilities	30.8	16.8	22.2	—	69.8
<b>Shareholder's Equity:</b>					
Common stock \$0.01 par value; 1,000 shares authorized, 100 shares issued	—	—	—	—	—
Additional paid in capital	1,074.2	—	—	—	1,074.2
Shareholder's equity	—	930.8	1,868.3	(2,799.1)	—
Accumulated deficit	(1,287.7)	—	—	—	(1,287.7)
Accumulated other comprehensive income/(loss)	60.3	(8.7)	(100.1)	—	(48.5)
<b>Total shareholder's equity</b>	<b>(153.2)</b>	<b>922.1</b>	<b>1,768.2</b>	<b>(2,799.1)</b>	<b>(262.0)</b>
Noncontrolling interest	—	—	(1.5)	—	(1.5)
<b>Total equity</b>	<b>(153.2)</b>	<b>922.1</b>	<b>1,766.7</b>	<b>(2,799.1)</b>	<b>(263.5)</b>
<b>Total liabilities and shareholder's equity</b>	<b>\$ 2,882.9</b>	<b>\$1,260.5</b>	<b>\$2,274.9</b>	<b>\$ (3,690.9)</b>	<b>\$ 2,727.4</b>

Catalent Pharma Solutions, Inc. and Subsidiaries  
Consolidating Statements of Cash Flows  
For the Six Months Ended December 31, 2010  
(In millions)

	Issuer	Guarantor	Non-Guarantor	Eliminations	Consolidated
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>					
Net earnings/(loss)	\$ (35.7)	\$ 63.4	\$ 21.6	\$ (84.4)	\$ (35.1)
Loss from discontinued operations	—	—	(0.2)	—	(0.2)
Earnings/(loss) from continuing operations	(35.7)	63.4	21.8	(84.4)	(34.9)
Adjustments to reconcile earnings/loss from continued operations to net cash from operations:					
Depreciation and amortization	—	26.4	33.7	—	60.1
Unrealized foreign currency transaction (gains)/losses, net	(2.1)	0.7	10.0	—	8.6
Amortization of debt financing costs	4.8	—	—	—	4.8
Deferral of interest through utilization of PIK	—	—	—	—	—
Asset impairments and (gain)/loss on sale of assets	0.2	(0.1)	—	—	0.1
Equity compensation	2.3	—	—	—	2.3
Income from subsidiaries	(84.4)	—	—	84.4	—
Provision (benefit) for deferred income taxes	0.6	2.9	(1.2)	—	2.3
Provisions for bad debts and inventory	—	2.0	3.0	—	5.0
Change in operating assets and liabilities, net of acquisitions:					
Decrease/(Increase) in trade receivables	—	(0.9)	29.9	—	29.0
Decrease/(Increase) in inventories	—	(3.2)	2.3	—	(0.9)
Increase/(Decrease) in accounts payable	—	(1.4)	(25.3)	—	(26.7)
Other accrued liabilities and operating items, net	2.6	(16.2)	(19.7)	—	(33.3)
Net cash provided by/(used in) operating activities from continuing operations	(111.7)	73.6	54.5	—	16.4
Net cash provided by/(used in) operating activities from discontinued operations	—	—	—	—	—
Net cash provided by/ (used in) operating activities	(111.7)	73.6	54.5	—	16.4
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>					
Proceeds from sale of property and equipment	—	—	3.6	—	3.6
Additions to property and equipment	—	(14.7)	(18.5)	—	(33.2)
Net cash used in investing activities from continuing operations	—	(14.7)	(14.9)	—	(29.6)
Net cash used in investing activities from discontinued operations	—	—	—	—	—
Net cash used in investing activities	—	(14.7)	(14.9)	—	(29.6)
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>					
Intercompany	63.9	(72.1)	8.2	—	—
Net change in short-term borrowings	(3.9)	—	(0.9)	—	(4.8)
Repayments in revolver credit facility	—	—	—	—	—
Borrowings from revolver credit facility	—	—	—	—	—
Repayments in long-term obligations	(7.1)	(0.8)	(4.7)	—	(12.6)
Distribution to non controlling interest holder	—	—	(2.6)	—	(2.6)
Equity (redemption) contribution	3.5	—	—	—	3.5
Net cash (used in)/ provided by financing activities from continuing operations	56.4	(72.9)	—	—	(16.5)
Net cash provided by/(used in) from discontinued operations	—	—	—	—	—
Net cash provided by/(used in) financing activities	56.4	(72.9)	—	—	(16.5)
Effect of foreign currency on cash	38.8	—	(32.4)	—	6.4
<b>NET INCREASE/(DECREASE) IN CASH AND EQUIVALENTS</b>					
	(16.5)	(14.0)	7.2	—	(23.3)
<b>CASH AND EQUIVALENTS AT BEGINNING OF PERIOD</b>					
	17.7	31.8	114.5	—	164.0
<b>CASH AND EQUIVALENTS AT END OF PERIOD</b>					
	\$ 1.2	\$ 17.8	\$ 121.7	\$ —	\$ 140.7

Catalent Pharma Solutions, Inc. and Subsidiaries  
Consolidating Statements of Cash Flows  
For the Six Months Ended December 31, 2009  
(In millions)

	Issuer	Guarantor	Non-Guarantor	Eliminations	Consolidated
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>					
Net earnings/(loss)	\$(293.4)	\$ (152.7)	\$ 21.2	\$ 130.6	\$ (294.3)
Loss from discontinued operations	—	(6.3)	—	—	(6.3)
Earnings/(loss) from continuing operations	(293.4)	(146.4)	21.2	130.6	(288.0)
Adjustments to reconcile earnings/loss from continued operations to net cash from operations:					
Depreciation and amortization	—	28.9	35.0	—	63.9
Unrealized foreign currency transaction (gains)/losses, net	0.2	0.3	14.2	—	14.7
Amortization of debt financing costs	4.8	—	—	—	4.8
Deferral of interest through utilization of PIK	29.0	—	—	—	29.0
Asset impairments and (gain)/loss on sale of assets	—	205.4	38.8	—	244.2
Equity compensation	0.2	—	—	—	0.2
Income from subsidiaries	130.6	—	—	(130.6)	—
Provision (benefit) for deferred income taxes	0.5	2.7	(9.5)	—	(6.3)
Provisions for bad debts and inventory	—	0.6	4.2	—	4.8
Change in operating assets and liabilities, net of acquisitions:					
Decrease/(Increase) in trade receivables	—	(7.4)	22.4	—	15.0
Decrease/(Increase) in inventories	—	7.6	5.5	—	13.1
Increase/(Decrease) in accounts payable	—	(9.5)	(3.5)	—	(13.0)
Other accrued liabilities and operating items, net	(6.0)	12.2	23.7	—	29.9
Net cash provided by/(used in) operating activities from continuing operations	(134.1)	94.4	152.0	—	112.3
Net cash provided by/(used in) operating activities from discontinued operations	—	(8.5)	—	—	(8.5)
Net cash provided by/ (used in) operating activities	(134.1)	85.9	152.0	—	103.8
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>					
Proceeds from sale of property and equipment	—	0.5	—	—	0.5
Additions to property and equipment	—	(7.8)	(29.0)	—	(36.8)
Net cash used in investing activities from continuing operations	—	(7.3)	(29.0)	—	(36.3)
Net cash used in investing activities from discontinued operations	—	—	—	—	10.5
Net cash used in investing activities	—	10.5	(29.0)	—	(25.8)
		3.2			
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>					
Intercompany	184.9	(79.9)	(105.0)	—	—
Net change in short-term borrowings	(4.2)	—	0.6	—	(3.6)
Repayments in revolver credit facility	(36.0)	—	—	—	(36.0)
Borrowings from revolver credit facility	—	—	—	—	—
Repayments in long-term obligations	(7.1)	(0.8)	(3.8)	—	(11.7)
Distribution to non controlling interest holder	—	—	(1.7)	—	(1.7)
Equity (redemption) contribution	0.5	—	—	—	0.5
Net cash (used in)/ provided by financing activities from continuing operations	138.1	(80.7)	(109.9)	—	(52.5)
Net cash provided by/(used in) from discontinued operations	—	—	—	—	—
Net cash provided by/(used in) financing activities	138.1	(80.7)	(109.9)	—	(52.5)
Effect of foreign currency on cash	—	—	0.8	—	0.8
<b>NET INCREASE/(DECREASE) IN CASH AND EQUIVALENTS</b>					
	4.0	8.4	13.9	—	26.3
<b>CASH AND EQUIVALENTS AT BEGINNING OF PERIOD</b>					
	—	4.3	59.6	—	63.9
<b>CASH AND EQUIVALENTS AT END OF PERIOD</b>					
	<u>\$ 4.0</u>	<u>\$ 12.7</u>	<u>\$ 73.5</u>	<u>\$ —</u>	<u>\$ 90.2</u>

## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

### The Company

Catalent Pharma Solutions, Inc. is one of the leading providers of advanced drug delivery technologies and outsourced development, manufacturing, and packaging services to the global pharmaceutical, biotechnology and consumer health industry. Our proprietary drug delivery and formulation technologies help our customers achieve their desired clinical and market outcomes and are used in many well-known products. Our business is organized in the following reportable segments: Oral Technologies, Sterile Technologies, Packaging Services and Development & Clinical Services. We believe that through our prior and ongoing investments in capacity, ongoing focus on operational excellence, innovation activities, the sales of existing products and introduction of new products by our customers, we will continue to benefit from attractive margins and from the growth potential in these areas.

### Critical Accounting Policies and Estimates

The preparation of financial statements are in conformity with generally accepted accounting principles and the release of *FASB Accounting Standards Codification*<sup>TM</sup> ("Codification") on July 1, 2009 ("GAAP"). These standards require management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts, inventory and long-lived asset valuation, goodwill and other intangible asset impairment, equity-based compensation, income taxes, derivative financial instruments, self insurance accruals, loss contingencies and restructuring charge reserves. Actual amounts may differ from these estimated amounts.

There were no material changes to the critical accounting policies or in the underlying accounting assumptions and estimates from those described in the Company's fiscal year 2010 Annual Report on Form 10-K, other than recently adopted accounting principles, none of which had a material impact.

### Recent Financial Accounting Standards

In April 2010, the FASB issued Accounting Standard Update 2010-17, "*Revenue Recognition – Milestone Method*", a standard that provides guidance on defining a milestone and determining when it may be appropriate to apply the milestone method of revenue recognition for certain research and development transactions. Under this new standard, a company can recognize as revenue consideration that is contingent upon achievement of a milestone in the period in which it is achieved, if the milestone meets all criteria to be considered substantive. This standard is effective on a prospective basis for periods beginning after July 1, 2010. The adoption of this update did not have a material effect on our consolidated financial statements.

In October 2009, the FASB issued Accounting Standard Update No. 2009-13 "*Multiple Deliverable Revenue Arrangements*", an amendment to the accounting standards related to the accounting for revenue derived from arrangements with multiple deliverables including how the arrangement consideration is allocated among delivered and undelivered items under the arrangement. Among the amendments, this standard eliminates the use of the residual method for allocating arrangement consideration and requires an entity to allocate the overall consideration to each deliverable based on an estimated selling price of each individual deliverable in the arrangement in the absence of having vendor-specific objective evidence or other third party evidence of fair value of the undelivered items. This standard also provides further guidance on how to determine a separate unit of accounting in a multiple-deliverable revenue arrangement and expands the disclosure requirements about the judgments made in applying the estimated selling price method and how those judgments affect the timing or amount of revenue recognition. We adopted this accounting standard in the first quarter of fiscal 2011 and adoption did not have a material impact on our consolidated financial statements.

### Results of Operations

#### *Use of EBITDA from continuing operations*

Management measures operating performance based on consolidated earnings from continuing operations before interest expense, expense/ (benefit) for income taxes, depreciation and amortization and is adjusted for the income or loss attributable to noncontrolling interest ("EBITDA from continuing operations"). EBITDA from continuing operations is not defined under U.S. GAAP and is not a measure of operating income, operating performance or liquidity presented in accordance with U.S. GAAP and is subject to important limitations.

We believe that the presentation of EBITDA from continuing operations enhances an investor's understanding of our financial performance. We believe this measure is a useful financial metric to assess our operating performance from period to period by excluding certain items that we believe are not representative of our core business and use this measure for business planning purposes. In addition, given the significant investments that we have made in the past in property, plant and equipment, depreciation and amortization expenses represent a meaningful portion of the Company's cost structure. We believe EBITDA from continuing

operations will provide investors with a useful tool for assessing the comparability between periods of our ability to generate cash from operations sufficient to pay taxes, to service debt and to undertake capital expenditures because it eliminates depreciation and amortization expense. We present EBITDA from continuing operations in order to provide supplemental information that we consider relevant for the readers of the financial statements, and such information is not meant to replace or supersede U.S. GAAP measures. Our definition of EBITDA from continuing operations may not be the same as similarly titled measures used by other companies.

In addition, the Company evaluates the performance of its segments based on segment earnings before noncontrolling interest, other (income)/expense, impairments, restructuring costs, interest expense, income tax (benefit)/expense, and depreciation and amortization (“Segment EBITDA”).

### **Three Months Ended December 31, 2010 compared to the Three Months Ended December 31, 2009**

Results for the three months ended December 31, 2010 compared to the three months ended December 31, 2009 are as follows:

(in millions)	Three Months Ended December 31, 2010	Three Months Ended December 31, 2009	Increase/(Decrease)	
			\$	%
Net revenue	\$ 413.1	\$ 433.5	\$(20.4)	-5%
Cost of products sold	290.9	315.1	(24.2)	-8%
Gross margin	122.2	118.4	3.8	3%
Selling, general and administrative expense	72.7	76.2	(3.5)	-5%
Impairment charges and (gain)/loss on sale of assets	(0.5)	0.2	(0.7)	*
Restructuring and other	5.0	4.5	0.5	11%
Operating earnings/(loss)	45.0	37.5	7.5	20%
Interest expense, net	41.2	44.1	(2.9)	-7%
Other (income)/expense, net	1.3	(9.5)	10.8	*
Earnings/(loss) from continuing operations before income taxes	2.5	2.9	(0.4)	-14%
Income tax expense/ (benefit)	9.3	18.4	(9.1)	-49%
Earnings/(loss) from continuing operations	(6.8)	(15.5)	8.7	-56%
Earnings/(loss) from discontinued operations	—	(5.3)	5.3	*
Net earnings/(loss)	(6.8)	(20.8)	14.0	-67%
Net earnings/(loss) attributable to noncontrolling interest	1.4	0.9	0.5	56%
Net earnings/(loss) attributable to Catalent	\$ (8.2)	\$ (21.7)	\$ 13.5	-62%

\* Percentage not meaningful

### **Net Revenue**

Net revenue decreased \$20.4 million, or 5%, compared to the same period a year ago. The stronger U.S. dollar unfavorably impacted revenue by approximately 3%, or \$11.5 million. Excluding the impact of foreign exchange, net revenue decreased by \$8.8 million, or 2%, during the three months ended December 31, 2010, primarily due to decreased demand within the Packaging Services and Sterile Technologies segments as a result of higher H1N1 flu volumes that the Company realized in the second quarter of the prior fiscal year as a result of the H1N1 pandemic in the prior fiscal year; partially offset by current quarter increased demand within our Oral Technologies and Development & Clinical Services segments. Within Oral Technologies, the increase was primarily driven by increased demand for prescription softgel products from several South American and European facilities. Within Development & Clinical Services, the increase was primarily driven by increased demand for analytical science services and biologics services within North America.

### **Gross Margin**

Gross margin increased \$3.8 million, or 3%, compared to the same period a year ago. The stronger U.S. dollar unfavorably impacted gross margin by approximately 3%, or \$3.6 million. Excluding the impact of foreign exchange, gross margin increased by \$7.5 million, or 6%, primarily due to the increased demand for prescription softgels and favorable product mix within the Oral Technologies segment as well as due to the revenue increase within the Development and Clinical Services segment; partially offset by the decreased demand within Packaging Services related to H1N1 volumes as compared to the prior year period.

### **Selling, General and Administrative Expense**

Selling, general and administrative expense decreased by approximately 5%, or \$3.5 million, compared to the comparable period of fiscal 2010. The stronger U.S. dollar decreased selling, general and administrative expense by approximately 2%, or \$1.5 million. Excluding the impact of foreign exchange, selling, general and administrative expenses decreased 2%, or \$1.9 million, as

compared to the same period a year ago primarily due to cost saving initiatives implemented across the Company's operating segments, as well as the timing of research and development expenses and investments in our sales and marketing functions.

### **Restructuring and Other**

Restructuring and other special items charges of \$5.0 million for the three months ended December 31, 2010 increased \$0.5 million compared to the same period from a year ago. The current period charges include asset impairment and real estate costs associated with facilities exited in prior periods and employee related restructuring charges.

### **Interest Expense, net**

Interest expense, net of \$41.2 million for the three months ended December 31, 2010 decreased \$2.9 million compared to the period ended December 31, 2009 was attributable to lower average foreign exchange rates as compared to the same period a year ago.

### **Other (Income)/Expense, net**

Other expense increased by \$10.8 million for the three months ended December 31, 2010 compared to the same three months of the prior fiscal year. This fluctuation primarily resulted from non-cash unrealized foreign currency transaction gains of \$2.1 million during the second quarter of fiscal year 2011 compared with \$12.9 million of non-cash unrealized foreign currency transaction gains recorded in the comparable prior year period.

### **Provision/(Benefit) for Income Taxes**

Our provision / (benefit) for income taxes for the three months ended December 31, 2010 was \$9.3 million relative to income before income taxes of \$2.5 million. Our provision / (benefit) for income taxes for the three months ended December 31, 2009 was \$18.4 million relative to income before income taxes of \$2.9 million. The income tax provision for the current period is not comparable to the same period of the prior year due to changes in pretax income over many jurisdictions and the impact of discrete items.

## Segment Review

The Company's results on a segment basis for the three months ended December 31, 2010 compared to the three months ended December 31, 2009 are as follows:

(in millions)	Three Months Ended December 31, 2010	Three Months Ended December 31, 2009	Increase/(Decrease)	
			\$	%
<b>Oral Technologies</b>				
Net revenue	\$ 261.5	\$ 262.1	\$ (0.6)	*
Segment EBITDA	66.6	62.6	4.0	6%
<b>Sterile Technologies</b>				
Net revenue	53.7	60.8	(7.1)	-12%
Segment EBITDA	8.3	8.0	0.3	4%
<b>Packaging Services</b>				
Net revenue	62.3	77.6	(15.3)	-20%
Segment EBITDA	0.6	7.2	(6.6)	-92%
<b>Development and Clinical Services</b>				
Net revenue	42.2	41.9	0.3	1%
Segment EBITDA	8.7	7.7	1.0	13%
<b>Inter-segment revenue elimination</b>				
	(6.6)	(8.9)	2.3	-26%
<b>Unallocated costs <sup>(1)</sup></b>				
	(11.2)	(7.9)	(3.3)	42%
<b>Combined Total</b>				
Net revenue	413.1	433.5	(20.4)	-5%
EBITDA from continuing operations	\$ 73.0	\$ 77.6	\$ (4.6)	-6%

\* Percentage not meaningful

(1) Unallocated costs includes equity-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:

(in millions)	Three Months Ended December 31, 2010	Three Months Ended December 31, 2009
Impairment charges and gain/(loss) on sale of assets	\$ 0.5	\$ (0.2)
Equity compensation	(0.9)	(1.3)
Restructuring and other special items	(7.0)	(8.3)
Sponsor advisory fee	(2.5)	(2.5)
Noncontrolling interest, net	(1.4)	(0.9)
Other income/(expense), net	(1.3)	9.5
Non-allocated corporate costs, net	1.4	(4.2)
Total unallocated costs	<u>\$ (11.2)</u>	<u>\$ (7.9)</u>

Provided below is a reconciliation of earnings/ (loss) from continuing operations to EBITDA from continuing operations

(in millions)	Three Months Ended December 31, 2010	Three Months Ended December 31, 2009
Earnings/(loss) from continuing operations	\$ (6.8)	\$ (15.5)
Depreciation and amortization	30.7	31.5
Interest expense, net	41.2	44.1
Income tax expense (benefit)	9.3	18.4
Noncontrolling interest	(1.4)	(0.9)
EBITDA from continuing operations	<u>\$ 73.0</u>	<u>\$ 77.6</u>

#### *Oral Technologies segment*

Net revenue was essentially flat compared to the same period a year ago. The stronger U.S. dollar negatively impacted revenue. Excluding the impact of foreign exchange rates, net revenue increased by 3%, or \$6.7 million. This increase was primarily related to increased demand for prescription and consumer health softgel products from several South American and European facilities, partially offset by near term decreased market demand for our customer's products which utilize our Zydis platform.

Segment EBITDA increased by 6%, or \$4.0 million. Oral Technologies' EBITDA was negatively impacted by the stronger U.S. dollar by approximately 3%, or \$2.1 million. Excluding the impact of foreign exchange rates, the increase was \$6.1 million, or 9%, and was primarily related to the previously mentioned demand increases for prescription and consumer health softgel products, as well as favorable product mix and overhead expense cost savings initiatives implemented within the segment.

#### *Sterile Technologies segment*

Net revenue decreased by 12%, or \$7.1 million. The stronger U.S. dollar negatively impacted revenue growth by approximately 4%, or \$2.5 million. Excluding the impact of foreign exchange rates, net revenues decreased 8%, or \$4.6 million, which was primarily driven by decreased demand for our pre-filled syringe offering as compared to the non-recurring H1N1 related volumes realized in same fiscal quarter of the prior year as a result of the H1N1 pandemic during the prior fiscal year period.

Segment EBITDA increased by 4%, or \$0.3 million. Sterile Technologies' EBITDA was negatively impacted by the stronger U.S. dollar by approximately 6%, or \$0.4 million. Excluding the impact of foreign exchange rates, the increase was 10%, or \$0.7 million, and was primarily attributable to an employee related government tax credit in a foreign jurisdiction and favorable product mix within the blow-fill-seal offering; partially offset by the volume declines attributable to the non-recurring H1N1 volumes the Company realized in the prior fiscal year.

#### *Packaging Services segment*

Net revenue decreased by 20%, or \$15.3 million. The stronger U.S. dollar negatively impacted the segment's revenue by approximately 1%, or \$0.9 million. Excluding the impact of foreign exchange rates, net revenue decreased by approximately 19%, or \$14.4 million, which was primarily related to lower demand within North American and European commercial packaging facilities as a result of non-recurring H1N1 flu volumes realized in the same fiscal quarter of the prior year as discussed above.

Segment EBITDA decreased 92%, or \$6.6 million. Segment EBITDA was negatively impacted by the stronger U.S. dollar by approximately 1%, or \$0.1 million. Excluding the impact of foreign exchange, the decrease of 91%, or \$6.5 million, was primarily related to lower demand at our North American and European commercial packaging facilities due to non-recurring H1N1 volumes from the prior fiscal year as discussed above.

#### *Development and Clinical Services segment*

Net revenue increased by 1%, or \$0.3 million. The stronger U.S. dollar negatively impacted the revenue growth by approximately 2%, or \$0.9 million. Excluding the impact of foreign exchange rates, net revenue increased 3%, or \$1.2 million, which was primarily driven by increased demand for analytical science services and biologics services within several North American facilities.

Segment EBITDA increased by 13%, or \$1.0 million. Segment EBITDA was negatively impacted by the stronger U.S. dollar by approximately 4%, or \$0.3 million. Excluding this impact, the increase was 17%, or \$1.3 million, which was primarily due to the aforementioned demand increase for analytical science services and biologics services within North America, as well as favorable product mix within our European clinical services facilities.

### Six Months Ended December 31, 2010 compared to the Six Months Ended December 31, 2009

Results for the six months ended December 31, 2010 compared to the six months ended December 31, 2009 are as follows:

(in millions)	Six Months Ended December 31, 2010	Six Months Ended December 31, 2009	Increase/(Decrease)	
			\$	%
Net revenue	\$ 815.2	\$ 849.1	\$ (33.9)	-4%
Cost of products sold	586.0	625.5	(39.5)	-6%
Gross margin	229.2	223.6	5.6	3%
Selling, general and administrative expense	147.5	146.7	0.8	1%
Impairment charges and (gain)/loss on sale of assets	0.1	244.2	(244.1)	*
Restructuring and other	10.6	7.1	3.5	49%
Operating earnings/(loss)	71.0	(174.4)	245.4	*
Interest expense, net	81.8	84.7	(2.9)	-3%
Other (income)/expense, net	13.4	21.1	(7.7)	-36%
Earnings/(loss) from continuing operations before income taxes	(24.2)	(280.2)	256.0	-91%
Income tax expense/ (benefit)	10.7	7.8	2.9	37%
Earnings/(loss) from continuing operations	(34.9)	(288.0)	253.1	-88%
Earnings/(loss) from discontinued operations	(0.2)	(6.3)	6.1	-97%
Net earnings/(loss)	(35.1)	(294.3)	259.2	-88%
Net earnings/(loss) attributable to noncontrolling interest	0.6	(0.9)	1.5	*
Net earnings/(loss) attributable to Catalent	\$ (35.7)	\$ (293.4)	\$ 257.7	-88%

\* Percentage not meaningful

#### Net Revenue

Net revenue decreased \$33.9 million, or 4%, compared to the same period a year ago. The stronger U.S. dollar unfavorably impacted revenue by approximately 3%, or \$27.6 million. Excluding the impact of foreign exchange, net revenue decreased by \$6.2 million, or 1%, during the six months ended December 31, 2010, primarily due to decreased demand within Packaging Services and Sterile Technologies; partially offset by increases within the Oral Technologies and Development & Clinical Services segments. The decrease in Packaging Services was driven by reduced demand for commercial packaging and printed components services, partially attributable to higher H1N1 flu related volumes that the Company realized in same period in the prior fiscal year as a result of the H1N1 pandemic. The Sterile Technologies decline was also primarily attributable to higher H1N1 flu related volumes from the prior fiscal year as well as certain customer volume declines within the blow-fill-seal technology platform. The Oral Technologies increase was a result of strong demand for prescription softgel products within several North American and European facilities, partially offset by near term decreased market demand for our customer's products which utilize our Zydis platform. The Development & Clinical Services volume increase was primarily related to strong demand for biologic and clinical services within North America.

#### Gross Margin

Gross margin increased \$5.6 million, or 3%, compared to the same period a year ago. The stronger U.S. dollar unfavorably impacted gross margin by approximately 4%, or \$8.2 million. Excluding the impact of foreign exchange, gross margin increased by \$13.9 million, or 7%, primarily due to product mix related to revenue increases within the Oral Technologies segment and the increased demand for biologic and clinical services within the Development and Clinical Services segment.

#### Selling, General and Administrative Expense

Selling, general and administrative expense increased by approximately 1%, or \$0.8 million, compared to the comparable period of fiscal 2011. The stronger U.S. dollar decreased selling, general and administrative expense by approximately 2%, or \$3.5 million. Excluding the impact of foreign exchange, selling, general and administrative expenses increased 3%, or \$4.4 million, as compared to the same period a year ago primarily due to an increase in research and development spending within our segments as compared to the same period in the prior year and investments in our sales and marketing functions.

#### Restructuring and Other

Restructuring and other special items charges of \$10.6 million for the six months ended December 31, 2010 increased \$3.5 million compared to the same period from a year ago. The charges for the six month ended December 31, 2010 included asset impairment and real estate charges related to planned facility consolidations announced in prior periods and employee related charges resulting from reductions in force to adjust the capacity of our workforce.

**Interest Expense, net**

Interest expense, net of \$81.8 million for the six months ended December 31, 2010 decreased \$2.9 million, primarily driven by the lower average foreign exchange rates compared to the six month period ended December 31, 2009.

**Other (Income)/Expense, net**

Other expense, net decreased by \$7.7 million for the six months ended December 31, 2010 compared to the same six months of the prior fiscal year. This fluctuation primarily resulted from recording non-cash unrealized foreign currency transaction losses of \$8.5 million during the six months of fiscal year 2011 compared with \$14.7 million of non-cash unrealized foreign currency transaction losses in the comparable prior year period. In addition, Euro hedge losses recorded in the prior year period totaled \$3.3 million as compared to zero during the six months ended December 31, 2010 due to the designation of the financial instrument for hedge accounting purposes effective October 1, 2010. These amounts were offset by an increase in realized foreign currency losses of approximately \$1.5 million.

**Provision/(Benefit) for Income Taxes**

The income tax provision / (benefit) relative to earnings / (loss) before income taxes, minority interest and discontinued operations was 44.2 % and 2.8% for the six months ended December 31, 2010 and 2009, respectively. Generally, fluctuations in the effective tax rate are primarily due to changes in our geographic pretax income resulting from our business mix and changes in the tax impact of permanent differences, restructuring, other special items and other discrete tax items, which may have unique tax implications depending on the nature of the item. Our effective tax rate reflects benefits derived from operations outside the United States, which are generally taxed at lower rates than the U.S. statutory rate of 35%.

## Segment Review

The Company's results on a segment basis for the six months ended December 31, 2010 compared to the six months ended December 31, 2009 are as follows:

(in millions)	Six Months Ended December 31, 2010	Six Months Ended December 31, 2009	Increase/(Decrease)	
			\$	%
<b>Oral Technologies</b>				
Net revenue	\$ 505.5	\$ 509.2	\$ (3.7)	-1%
Segment EBITDA	118.8	112.3	6.5	6%
<b>Sterile Technologies</b>				
Net revenue	107.4	122.2	(14.8)	-12%
Segment EBITDA	13.5	18.5	(5.0)	-27%
<b>Packaging Services</b>				
Net revenue	130.6	150.0	(19.4)	-13%
Segment EBITDA	3.7	10.8	(7.1)	-66%
<b>Development and Clinical Services</b>				
Net revenue	85.6	82.4	3.2	4%
Segment EBITDA	17.6	13.5	4.1	30%
<b>Inter-segment revenue elimination</b>	(13.9)	(14.7)	0.8	-5%
<b>Unallocated costs <sup>(1)</sup></b>	(36.5)	(285.8)	249.3	-87%
<b>Combined Total</b>				
Net revenue	815.2	849.1	(33.9)	-4%
EBITDA from continuing operations	\$ 117.1	\$ (130.7)	\$ 247.8	*

\* Percentage not meaningful

(2) Unallocated costs includes equity-based compensation, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:

(in millions)	Six Months Ended December 31, 2010	Six Months Ended December 31, 2009
Impairment charges and gain/(loss) on sale of assets	\$ (0.1)	\$ (244.2)
Equity compensation	(2.3)	(0.2)
Restructuring and other special items	(15.2)	(12.1)
Sponsor advisory fee	(5.0)	(5.0)
Noncontrolling interest, net	(0.6)	0.9
Other income/(expense), net	(13.4)	(21.1)
Non-allocated corporate costs, net	0.1	(4.1)
Total unallocated costs	\$ (36.5)	\$ (285.8)

Provided below is a reconciliation of earnings/ (loss) from continuing operations to EBITDA from continuing operations

(in millions)	Six Months Ended December 31, 2010	Six Months Ended December 31, 2009
Earnings/(loss) from continuing operations	\$ (34.9)	\$ (288.0)
Depreciation and amortization	60.1	63.9
Interest expense, net	81.8	84.7
Income tax expense (benefit)	10.7	7.8
Noncontrolling interest	(0.6)	0.9
EBITDA from continuing operations	\$ 117.1	\$ (130.7)

#### *Oral Technologies segment*

Net revenue decreased by 1%, or \$3.7 million, compared to the same period a year ago. The stronger U.S. dollar negatively impacted revenue totals by approximately 3%, or \$16.4 million. Excluding the impact of foreign exchange rates, net revenue increased by 2%, or \$12.7 million. This increase was primarily related to increased demand for prescription and consumer health softgel products from several North American, South American and European facilities, partially offset by near term decreased market demand for our customer's products which utilize our Zydis platform.

Segment EBITDA increased by 6%, or \$6.5 million. Oral Technologies' EBITDA was negatively impacted by the stronger U.S. dollar by approximately 4%, or \$4.0 million. Excluding the impact of foreign exchange rates, the increase was \$10.5 million, or 10%, which was primarily related to the previously mentioned demand increases for prescription and consumer health products and favorable product mix at several facilities; partially offset by the decreased demand for Zydis products as discussed above.

#### *Sterile Technologies segment*

Net revenue decreased by 12%, or \$14.8 million. The stronger U.S. dollar negatively impacted revenue growth by approximately 5%, or \$6.3 million. Excluding the impact of foreign exchange rates, net revenues decreased 7%, or \$8.5 million, which was primarily driven by lower certain customer volume declines within the blow-fill-seal offering, and decreased volumes within one of the European injectable facilities as a result of non-recurring H1N1 related volumes that were realized during the same period of the prior fiscal year as discussed above.

Segment EBITDA decreased by 27%, or \$5.0 million. Sterile Technologies' EBITDA was negatively impacted by the stronger U.S. dollar by approximately 7%, or \$1.3 million. Excluding the impact of foreign exchange rates, the decrease was 20%, or \$3.7 million. The decrease was due to the volume declines within the European injectable facilities and the blow-fill-seal offering, as discussed above.

#### *Packaging Services segment*

Net revenue decreased by 13%, or \$19.4 million. The stronger U.S. dollar negatively impacted the segment's revenue growth by approximately 2%, or \$2.4 million. Excluding the impact of foreign exchange rates, net revenue decreased by approximately 11%, or \$17.0 million, which was primarily related to lower demand within North American and European commercial packaging facilities, which is partially attributable to non-recurring H1N1 flu related volumes that were realized in the same period of the prior fiscal year as discussed above.

Segment EBITDA decreased 66%, or \$7.1 million. Segment EBITDA was negatively impacted by the stronger U.S. dollar by approximately 2%, or \$0.2 million. Excluding the impact of foreign exchange rates, the decrease of 64%, or \$6.9 million, was primarily related to lower demand at our North American and European commercial packaging facilities partially related to the non-recurring H1N1 flu volumes occurring in the prior fiscal year as described above, partially offset by the implementation of selling, general and administration cost saving efficiencies and manufacturing indirect cost savings across the segment.

#### *Development and Clinical Services segment*

Net revenue increased by 4%, or \$3.2 million. The stronger U.S. dollar negatively impacted the revenue growth by approximately 3%, or \$2.6 million. Excluding the impact of foreign exchange rates, revenues increased 7%, or \$5.8 million, which was primarily driven by increased demand for biologics services and for clinical services projects within several North American facilities.

Segment EBITDA increased by 30%, or \$4.1 million. Segment EBITDA was negatively impacted by the stronger U.S. dollar by approximately 7%, or \$1.0 million. Excluding this impact, the increase was 37%, or \$5.2 million, which was primarily due to the aforementioned demand increase for biologics services and clinical services projects.

## Liquidity and Capital Resources

### Sources and Uses of Cash

The Company's principal source of liquidity has been cash flow generated from operations. The principal uses of cash are to fund planned operating and capital expenditures, interest payments on debt and any mandatory or discretionary principal payments on debt issuances. As of December 31, 2010, the Company's financing needs were supported by a \$350.0 million revolving credit agreement, which was reduced by \$15.0 million of outstanding letters of credit. The revolving credit agreement matures April 10, 2013. As of December 31, 2010, we had no outstanding borrowings under the Company's revolving credit agreement.

The Company has the option every six months until April 15, 2011, at its election, to use the payment-in-kind ("PIK") feature of its \$565 million 9 1/2% /10 1/4 % Senior PIK-Election Notes due 2015 (the "Senior Toggle Notes") in lieu of making cash interest payments. While the Company had sufficient liquidity to meet its anticipated ongoing needs without use of this PIK feature, the Company elected to do so for the October 15, 2009 and April 15, 2010 interest payment dates as an efficient and cost-effective method to further enhance liquidity in light of the substantial dislocation in the financial markets at that time. During the PIK election period, the Senior Toggle Notes were subject to the PIK interest rate of 10 1/4%. For the interest period ending on October 15, 2010, the Company made such interest payment entirely in cash.

In connection with this election, on April 12, 2010, we delivered notice to The Bank of New York Mellon (formerly known as The Bank of New York), in its capacity as trustee under the indenture for the Company's outstanding Senior Toggle Notes, that, with respect to the interest due on such notes on the October 15, 2010 interest payment date, the Company would make such interest payment entirely in cash at the cash interest rate of 9.50%. As a result, the entirely cash interest election became the default election and the Company did not elect to change the cash interest election for the final interest election period ending April 15, 2011. Therefore, all remaining interest payments on the Senior Toggle Notes are to be paid entirely in cash in accordance with the terms of the indenture.

We continue to believe that the Company's cash from operations and available borrowings under the revolving credit facility will be adequate to meet the Company's future liquidity needs for at least the next twelve months.

### Cash Flows

The following table summarizes the Company's statement of cash flows from continuing operations:

(in millions)	Six Months Ended December 31, 2010	Six Months Ended December 31, 2009	\$ Change
Net cash provided by/(used in):			
Operating activities	\$ 16.4	\$ 112.3	\$ (95.9)
Investing activities	(29.6)	(36.3)	6.7
Financing activities	(16.5)	(52.5)	36.0

#### Operating activities

For the six month period ended December 31, 2010, cash provided by operating activities was \$16.4 million compared to cash provided by operating activities of \$112.3 million for the six month period ended December 31, 2009. The reduction was primarily driven by changes in foreign exchange rates impacting our liability accounts and the impact of our income tax provision on our accrued income tax payable balance. In addition, cash flow generation was lower in the current year period due to our election to cease using the PIK feature of the Senior Toggle Notes and to pay cash interest for the interest period ending on October 15, 2010.

#### Investing activities

For the six month period ended December 31, 2010, cash used in investing activities was \$29.6 million, a decrease of \$6.7 million compared to the six month period ending December 31, 2009, attributable to lower capital expenditures.

#### Financing activities

For the six month period ended December 31, 2010, cash used in financing activities was \$16.5 million compared to cash used by financing activities of \$52.5 million in the same period a year ago. The year over year fluctuation was primarily attributable to the repayments of \$36.0 million of borrowings from our revolving credit facility in prior year period, with no such payment being made in the current year period.

## Debt and Financing Arrangements

The Company uses interest rate swaps to manage the economic effect of variable rate interest obligations associated with our floating rate term loans so that the interest payable on the term loans effectively becomes fixed at a certain rate, thereby reducing the impact of future interest rate changes on our future interest expense. As of December 31, 2010, we had four interest rate swap agreements that have the economic effect of modifying the variable interest obligations associated with our floating rate term loans. These agreements include two U.S. dollar-denominated, one Euro-denominated and one Yen-denominated interest rate swap agreements. The unrealized losses on our interest rate swaps that are designated as effective cash flow hedges for accounting purposes were \$4.1 million, net of tax and are recorded within Accumulated Other Comprehensive Loss on our balance sheet at December 31, 2010.

The current Japanese Yen interest rate swap was designed as an effective economic hedge but not designated as effective for financial reporting purposes and is included in the Consolidated Statements of Operations as Other (Income)/Expense. Conversely, unrealized gains/losses on the U.S. Dollar and Euro interest rate swaps are designated as effective hedges and are included in Accumulated Other Comprehensive Income/(Loss) and the corresponding payables are included in other current liabilities in our Consolidated Balance Sheet.

As of December 31, 2010, the Company was in compliance with all restrictive covenants related to its long-term obligations

## Guarantees and Security

All obligations under the senior secured credit agreement, the Senior Toggle Notes and the Senior Subordinated Notes (together, the “notes”) are unconditionally guaranteed by each of the Company’s existing U.S. wholly-owned subsidiaries, other than the Company’s Puerto Rico subsidiaries, subject to certain exceptions.

All obligations under the Senior Secured Credit Facilities, and the guarantees of those obligations, are secured by substantially all of the following assets of the Company and each guarantor, subject to certain exceptions:

- a pledge of 100% of the capital stock of the Company and 100% of the equity interests directly held by the Company and each guarantor in any wholly-owned material subsidiary of the Company or any guarantor (which pledge, in the case of any non-U.S. subsidiary of a U.S. subsidiary, will not include more than 65% of the voting stock of such non-U.S. subsidiary); and
- a security interest in, and mortgages on, substantially all tangible and intangible assets of the Company and of each guarantor, subject to certain limited exceptions.

## Debt Covenants

The senior secured credit agreement and the indentures governing the Senior Toggle Notes and the Senior Subordinated Notes contain a number of covenants that, among other things, restrict, subject to certain exceptions, the Company’s (and the Company’s restricted subsidiaries’) ability to incur additional indebtedness or issue certain preferred shares; create liens on assets; engage in mergers and consolidations; sell assets; pay dividends and distributions or repurchase capital stock; repay subordinated indebtedness; engage in certain transactions with affiliates; make investments, loans or advances; make certain acquisitions; in the case of the Company’s senior credit agreement, enter into sale and leaseback transactions, amend material agreements governing the Company’s subordinated indebtedness (including the Senior Subordinated Notes) and change the Company’s lines of business.

The senior credit facility and indentures governing the Senior Toggle Notes and the Senior Subordinated Notes also contain change of control provisions and certain customary affirmative covenants and events of default. As of December 31, 2010, the Company was in compliance with all covenants related to its long-term obligations. The Company’s long-term debt obligations do not contain any financial maintenance covenants.

Subject to certain exceptions, the senior credit agreement and the indentures governing the notes will permit the Company and its restricted subsidiaries to incur additional indebtedness, including secured indebtedness. None of the Company’s non-U.S. subsidiaries or Puerto Rico subsidiaries is a guarantor of the loans or notes.

As market conditions warrant and subject to the Company’s contractual restrictions and liquidity position, we, the Company’s affiliates and/or the Company’s major equity holders, including Blackstone and its affiliates, may from time to time repurchase the Company’s outstanding debt securities, including the Senior Toggle Notes and the Senior Subordinated Notes and/or the Company’s outstanding bank loans in privately negotiated or open market transactions, by tender or otherwise. Any such repurchases may be funded by incurring new debt, including additional borrowings under the Company’s existing credit facility. Any new debt may also be secured debt. We may also use available cash on the Company’s balance sheet. The amounts involved in any such transactions, individually or in the aggregate, may be material. Further, any such purchases may result in the Company’s acquiring and retiring a substantial amount of any particular series, with the attendant reduction in the trading liquidity of any such series.

Under the indentures governing the notes, the Company's ability to engage in certain activities such as incurring certain additional indebtedness, making certain investments and paying certain dividends is tied to ratios based on Adjusted EBITDA (which is defined as "EBITDA" in the indentures).

Adjusted EBITDA is based on the definitions in the Company's indentures, is not defined under U.S. GAAP, and is subject to important limitations. We have included the calculations of Adjusted EBITDA for the period presented below as Adjusted EBITDA is the covenant compliance measure used in certain covenants under the indentures governing the notes, particularly those governing debt incurrence and restricted payments. Because not all companies use identical calculations, the Company's presentation of Adjusted EBITDA may not be comparable to other similarly titled measures of other companies.

### Adjusted EBITDA

In calculating Adjusted EBITDA, we add back certain non-cash, non-recurring and other items that are included in the definitions of EBITDA and consolidated net income as required in the indentures governing the notes. Adjusted EBITDA, among other things:

- does not include non-cash, stock-based employee compensation expense and certain other non-cash charges;
- does not include cash and non-cash restructuring, severance and relocation costs incurred to realize future cost savings and enhance the Company's operations;
- adds back noncontrolling interest expense, which represents noncontrolling investors' ownership of certain of the Company's consolidated subsidiaries and is, therefore, not available to us; and
- includes estimated cost savings which have not yet been fully reflected in the Company's results.

The Company's Adjusted EBITDA for the last twelve months ended December 31, 2010 based on the definitions in the Company's indentures is calculated as follows:

(in millions)	Trailing Twelve Months Ended December 31, 2010
Loss from continuing operations	\$ (29.1)
Interest expense, net	157.9
Income tax (benefit)/expense	24.5
Depreciation and amortization	122.6
Noncontrolling interest	(4.1)
EBITDA from continuing operations	271.8
Equity compensation <sup>(1)</sup>	4.7
Impairment charges and (gain)/loss on sale of assets <sup>(2)</sup>	4.5
Restructuring and other special items <sup>(3)</sup>	43.0
Unrealized Foreign exchange loss/(gain) (included in other expense (income), net) <sup>(4)</sup>	(9.7)
Other adjustments	3.2
Advisory monitoring fee <sup>(5)</sup>	10.0
Subtotal	327.5
Estimated cost savings	—
Adjusted EBITDA	\$ 327.5

<sup>(1)</sup> Reflects non-cash stock-based compensation expense under the provisions of ASC 718 *Compensation – Stock Compensation*.

<sup>(2)</sup> Reflects non-cash asset impairment charges and losses from the sale of assets not included in restructuring and other special items discussed below.

<sup>(3)</sup> Restructuring and other special charges of \$43.0 million were primarily attributable to restructuring activities which focus on various aspects of operations, including consolidating certain operations, rationalizing headcount and aligning operations in a more strategic and cost-efficient structure.

<sup>(4)</sup> Reflects \$34.4 million of unrealized foreign currency translation recorded on inter-company loans denominated in a currency different from the functional currency of either the borrower or the lender. These unrealized gains were offset by the exclusion of realized foreign currency exchange rate losses from the non-cash and cash settlement of inter-company loans of \$15.9 million and \$8.9 million, respectively. Inter-company loans are between Catalent entities and do not reflect the ongoing results of the companies trade operations. These inter-company foreign exchange gains and losses were offset by \$0.1 million of unrealized gains from our interest rate swap derivative agreements.

<sup>(5)</sup> Represents amount of sponsor advisory fee. See Related Party Transactions (Note 10) of the unaudited Consolidated Financial Statements.

## **Interest Risk Management**

A portion of the debt used to finance the Company's operations is exposed to interest rate fluctuations. We may use various hedging strategies and derivative financial instruments to create an appropriate mix of fixed and floating rate assets and liabilities. The primary interest rate exposure as of December 31, 2010 is to interest rate fluctuations in the United States and Europe, especially USD LIBOR and EURIBOR interest rates. We currently use interest rate swaps as the derivative instruments in these hedging strategies. The derivatives used to manage the risk associated with the Company's floating USD LIBOR and EURIBOR rate debt were designated as effective cash flow hedges. The derivative used to manage the risk associated with the Company's floating TIBOR (Tokyo inter-bank Domestic Yen Offered rate) rate debt is an effective economic hedge but is not designated as an effective cash flow hedge for financial reporting purposes.

## **Currency Risk Management**

The Company is exposed to fluctuations in the EUR-USD exchange rate on its investments in foreign operations in Europe. While the Company does not actively hedge against changes in foreign currency, we have mitigated the exposure of our investments in our European operations by denominating a portion of our debt in Euros. At December 31, 2010, the Company had Euro denominated debt outstanding of \$619.0 million that qualifies as a hedge of a net investment in foreign operations. For non-derivatives designated and qualifying as net investment hedges, the effective portion of the translation gains or losses are reported in Accumulated Other Comprehensive Income (Loss) as part of the cumulative translation adjustment. During the six months ended December 31, 2010, the Company recorded \$38.8 million as a loss within cumulative translation adjustment. The net accumulated gain of this net investment as of December 31, 2010 included within Other Comprehensive Income was approximately \$69.9 million. Amounts are reclassified out of Accumulated Other Comprehensive Income into earnings when the hedged net investment is either sold or substantially liquidated.

Periodically, we may utilize forward currency exchange contracts to manage the Company's exposures to the variability of cash flows primarily related to the foreign exchange rate changes of future foreign currency transaction costs. In addition, we may utilize foreign currency forward contracts to protect the value of existing foreign currency assets and liabilities. Currently, we do not utilize foreign currency exchange contracts. We expect to continue to evaluate hedging opportunities for foreign currency in the future.

## **Contractual Obligations**

There have been no material changes outside the ordinary course of business since June 30, 2010 with respect to the contractual obligations disclosed in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2010.

## **Off-Balance Sheet Arrangements**

Other than operating leases, we do not have any off-balance sheet arrangements as of December 31, 2010.

## **Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

We are exposed to cash flow and earnings fluctuations as a result of certain market risks. These market risks primarily relate to changes in interest rates associated with our long-term debt obligations and foreign exchange rate changes. We utilize derivative financial instruments, such as interest rate swaps, in order to mitigate risk associated with our variable rate debt.

### ***Interest Rate Risk***

The Company uses interest rate swaps to manage the economic effect of variable rate interest obligations associated with our floating rate term loans and so that the interest payable on the term loans effectively becomes fixed at a certain rate, thereby reducing the impact of future interest rate changes on our future interest expense. As of December 31, 2010, we had four interest rate swap agreements that have the economic effect of modifying the variable interest obligations associated with our floating rate term loans due in April and May 2013. These agreements include two U.S dollar-denominated, one Euro-denominated and one Yen-denominated interest rate swap agreements.

As of December 31, 2010, the Company had four outstanding interest rate derivatives, three of which were effective December 31, 2010 with a combined notional value of \$760.0 million and €240.0 million. These instruments are designated for financial accounting purposes as cash flow hedges of interest rate risk. Amounts reported in Accumulated Other Comprehensive Income related to derivatives will be reclassified to interest expense as interest payments are made on the Company's variable-rate debt. In addition, the Company has a Japanese Yen interest rate swap which is economically effective but is not designated as an effective hedge for financial reporting and is included in the Consolidated Statements of Operations as Other (Income)/Expense.

### **Foreign Currency Exchange Risk**

By nature of our global operations, we are exposed to cash flow and earnings fluctuations resulting from foreign exchange rate variation. These exposures are transactional and translational in nature. Since we manufacture and sell our products throughout the world, our foreign currency risk is diversified. Principal drivers of this diversified foreign exchange exposure include the European Euro, British pound, Argentinean peso, Brazilian real and Australian dollar. Our transactional exposure arises from the purchase and sale of goods and services in currencies other than the functional currency of our operational units. We also have exposure related to the translation of financial statements of our foreign divisions into U.S. dollars, the functional currency of the parent. The financial statements of our operations outside the U.S. are measured using the local currency as the functional currency. Adjustments to translate the assets and liabilities of these foreign operations in U.S. dollars are accumulated as a component of other comprehensive income utilizing period-end exchange rates. Foreign currency transaction gains and losses calculated by utilizing weighted average exchange rates for the period are included in the statements of operations in "other expense, net". Such foreign currency transaction gains and losses include inter-company loans denominated in non- U.S. dollar currencies.

## **Item 4. CONTROLS AND PROCEDURES**

### **Disclosure Controls and Procedures**

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company's reports under the Securities Exchange Act of 1934, as amended ("Exchange Act") is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission's ("SEC") rules and forms, and that such information is accumulated and communicated to the Company's management, including the Company's President and Chief Executive Officer, and the Company's Senior Vice President and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. The Company's management, with the participation of the Company's President and Chief Executive Officer, and the Company's Senior Vice President and Chief Financial Officer, has evaluated the effectiveness of the design and operation of the Company's disclosure controls and procedures as of the end of the period covered by this Form 10-Q. Based upon that evaluation, the Company's President and Chief Executive Officer and the Company's Senior Vice President and Chief Financial Officer concluded that, as of December 31, 2010, the Company's disclosure controls and procedures were effective to accomplish their objectives at the reasonable assurance level.

### **Changes in Internal Control over Financial Reporting**

There was no change in the Company's internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

## **PART II—OTHER INFORMATION**

### **Item 1. LEGAL PROCEEDINGS**

Beginning in November 2006, the Company, along with several pharmaceutical companies, has been named in civil lawsuits filed by individuals allegedly injured by their use of the prescription acne medication Amnesteem®, a branded generic form of isotretinoin, and in some instances of isotretinoin products made and/or sold by other firms as well. Currently, the Company is a named defendant in one hundred and seventy-five pending isotretinoin lawsuits. Plaintiffs allege that they suffer from inflammatory bowel disease and other disorders as a result of their ingestion of Amnesteem. The geographic distribution of these one hundred and seventy-five lawsuits is as follows: one in the U.S. District Court for the Middle District of North Carolina that has been transferred to the Accutane® (Isotretinoin) federal Multi-District Litigation ("Accutane MDL") in the Middle District of Florida; two in the Court of Common Pleas, Washington County, Pennsylvania; and one hundred seventy-two in the Superior Court, Atlantic County, New Jersey. The New Jersey cases and several of the other cases have been brought by a consortium of plaintiffs' law firms, including Seeger Weiss. The following discussion contains more detail about the lawsuits.

One hundred seventy-two lawsuits are pending in the Superior Court of New Jersey, Law Division, Atlantic County by individual plaintiffs who claim to have ingested Amnesteem, and, in some cases, one or more competing branded generic isotretinoin products, including Sotret® (Ranbaxy) and/or Claravis® (Barr), as well as Accutane (the pioneer isotretinoin product sold by Hoffmann-La Roche). Sixty-five of these cases allegedly involve the use of both Accutane and one or more of the branded generic forms of isotretinoin. Such cases, which include one or more Roche entities as defendants, are filed as part of the New Jersey consolidated mass tort proceeding set up in 2005 for all Accutane lawsuits pending in New Jersey state courts. The remaining one hundred and seven cases do not involve the use of Accutane, but allegedly involve the use of one or more branded generic isotretinoin products, including Amnesteem. These cases are not part of the Accutane mass tort litigation; these non-mass tort, generics-only cases have been consolidated for discovery purposes but not for trial. All one hundred seventy-two of the cases pending in New Jersey, both mass tort and non-mass tort, are assigned to the same judge. In addition to the Company, these lawsuits name the pharmaceutical companies whose respective isotretinoin products each plaintiff allegedly ingested.

Two lawsuits involving only Amnesteem use are pending in the Court of Common Pleas, Washington, County, Pennsylvania. One lawsuit was filed in the General Court of Justice, Superior Court Division, Durham County, North Carolina, but was removed to the United States District Court for the Middle District of North Carolina, Durham Division. Pursuant to a tolling agreement, the case had been dismissed without prejudice pending the outcome of the United States Court of Appeals for the Eleventh Circuit's review of the decision of the Accutane MDL Court to exclude plaintiff's general causation expert. On August 26, 2008, the Eleventh Circuit affirmed the exclusion of plaintiff's expert, and a subsequent petition for rehearing was denied. Plaintiffs have since re-filed the case in the Middle District of North Carolina and the Company successfully moved to transfer the case to the Accutane MDL in the Middle District of Florida.

One lawsuit appearing to involve only Amnesteem use was served on the Company in February 2009 and had been pending in the District Court of Bowie County, Texas. This plaintiff ultimately dismissed his Texas lawsuit, shortly after filing a new lawsuit in New Jersey, and this New Jersey lawsuit is included among the above-referenced one hundred and three consolidated non-mass tort cases.

One lawsuit allegedly involving Amnesteem, Claravis and Accutane ingestions had been filed in the Circuit Court, Cook County, Illinois. The Company was dismissed from the suit without prejudice in June 2010.

One lawsuit allegedly involving Amnesteem and Claravis filed in the Superior Court, Atlantic County, New Jersey was dismissed on September 17, 2010.

Although expressed in various terms, generally speaking, all one hundred and seventy-five lawsuits set forth some or all of the standard array of product liability claims, including strict liability for defective design, strict liability for failure to warn, negligence (in both design and warnings), fraud and misrepresentation, and breach of warranty. The lawsuits seek unspecified amounts of compensatory and punitive damages. The Company believes it has valid defenses to these lawsuits and intends to vigorously defend them.

From time to time, we may be involved in legal proceedings arising in the ordinary course of business, including, without limitation, inquiries and claims concerning environmental contamination as well as litigation and allegations in connection with acquisitions, product liability, manufacturing or packaging defects and claims for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of which could be significant. We intend to vigorously defend ourselves against such other litigation and do not currently believe that the outcome of any such other litigation will have a material adverse effect on our financial statements. In addition, the healthcare industry is highly regulated and government agencies continue to scrutinize certain practices affecting government programs and otherwise.

From time to time, we receive subpoenas or requests for information from various government agencies, including from state attorneys general and the U.S. Department of Justice relating to the business practices of customers or suppliers. We generally respond to such subpoenas and requests in a timely and thorough manner, which responses sometimes require considerable time and effort and can result in considerable costs being incurred by us. We expect to incur additional costs in the future in connection with existing and future requests.

#### **Item 1A. RISK FACTORS**

In addition to the other information set forth in this report, you should carefully consider the factors discussed in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2010 which could materially affect the Company's business, financial condition or future results. The risks described in the Company's Annual Report on Form 10-K are not the only risks facing the Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect the Company's business, financial condition and/or operating results. There have been no material changes to the risk factors disclosed in the Company's Annual Report on Form 10-K.

#### **Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

None.

#### **Item 3. DEFAULTS UPON SENIOR SECURITIES**

None.

#### **Item 4. [REMOVED AND RESERVED]**

#### **Item 5. OTHER INFORMATION**

None.

**Item 6. EXHIBITS**

Exhibits:

- 31.1 Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended\*
- 31.2 Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended\*
- 32.1 Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002\*\*
- 32.2 Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002\*\*

\* Filed herewith

\*\* Furnished herewith.

† Represents management contract, compensatory plan or arrangement in which directors and/or executive officers are eligible to participate.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CATALENT PHARMA SOLUTIONS, INC.  
(REGISTRANT)

Date: February 10, 2011

By: /s/ John R. Chiminski  
John R. Chiminski  
President & Chief Executive Officer

Date: February 10, 2011

By: /s/ Matthew M. Walsh  
Matthew M. Walsh  
Senior Vice President & Chief Financial Officer

**CHIEF EXECUTIVE OFFICER CERTIFICATION**

I, John R. Chiminski, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ended December 31, 2010 of Catalent Pharma Solutions, Inc. (the "Registrant");

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4. The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

5. The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

Dated: February 10, 2011

/s/ John R. Chiminski  
\_\_\_\_\_  
**John R. Chiminski**  
**President and Chief Executive Officer**  
**(Principal Executive Officer)**

**CHIEF FINANCIAL OFFICER CERTIFICATION**

I, Matthew M. Walsh, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the period ended December 31, 2010 of Catalent Pharma Solutions, Inc. (the "Registrant");

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4. The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

5. The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

Dated: February 10, 2011

/s/ Matthew M. Walsh  
\_\_\_\_\_  
**Matthew M. Walsh**  
**Senior Vice President and**  
**Chief Financial Officer**  
**(Principal Financial Officer)**

**Certification of the Chief Executive Officer  
Pursuant to 18 U.S.C. Section 1350,  
As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of Catalent Pharma Solutions, Inc. (the "Company") on Form 10-Q for the period ended December 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, John R. Chiminski, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 10, 2011

\_\_\_\_\_  
/s/ John R. Chiminski  
**John R. Chiminski**  
**President and**  
**Chief Executive Officer**

**Certification of the Chief Financial Officer  
Pursuant to 18 U.S.C. Section 1350,  
As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of Catalent Pharma Solutions, Inc. (the "Company") on Form 10-Q for the period ended December 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Matthew M. Walsh, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 10, 2011

\_\_\_\_\_  
/s/ Matthew M. Walsh  
**Matthew M. Walsh**  
**Senior Vice President and**  
**Chief Financial Officer**